CA1078387A - Benzoylpiperidylalkylindoles and related compounds - Google Patents
Benzoylpiperidylalkylindoles and related compoundsInfo
- Publication number
- CA1078387A CA1078387A CA273,782A CA273782A CA1078387A CA 1078387 A CA1078387 A CA 1078387A CA 273782 A CA273782 A CA 273782A CA 1078387 A CA1078387 A CA 1078387A
- Authority
- CA
- Canada
- Prior art keywords
- indole
- piperidyl
- ethyl
- reacted
- piperidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 67
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 102
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 81
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 69
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 54
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 52
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 52
- 125000005936 piperidyl group Chemical group 0.000 claims description 27
- NTLAICDKHHQUGC-UHFFFAOYSA-N 3-(2-bromoethyl)-1h-indole Chemical compound C1=CC=C2C(CCBr)=CNC2=C1 NTLAICDKHHQUGC-UHFFFAOYSA-N 0.000 claims description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 23
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 22
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 22
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 12
- -1 hydroxy, phenoxy Chemical group 0.000 claims description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 7
- DDRCHUGHUHZNKZ-UHFFFAOYSA-N phenyl(piperidin-4-yl)methanone Chemical compound C=1C=CC=CC=1C(=O)C1CCNCC1 DDRCHUGHUHZNKZ-UHFFFAOYSA-N 0.000 claims description 7
- ABERUOJGWHYBJL-UHFFFAOYSA-N (4-fluorophenyl)-piperidin-4-ylmethanone Chemical compound C1=CC(F)=CC=C1C(=O)C1CCNCC1 ABERUOJGWHYBJL-UHFFFAOYSA-N 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 239000007789 gas Substances 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- KXIQYMPUCUEPHF-UHFFFAOYSA-N (2-fluoro-4-methylphenyl)-piperidin-4-ylmethanone;hydrochloride Chemical compound Cl.FC1=CC(C)=CC=C1C(=O)C1CCNCC1 KXIQYMPUCUEPHF-UHFFFAOYSA-N 0.000 claims description 3
- NOCFQMBSDJUUBB-UHFFFAOYSA-N (2-fluorophenyl)-piperidin-4-ylmethanone;hydrochloride Chemical compound Cl.FC1=CC=CC=C1C(=O)C1CCNCC1 NOCFQMBSDJUUBB-UHFFFAOYSA-N 0.000 claims description 3
- MEKSXLSAYLIUHI-UHFFFAOYSA-N (2-hydroxy-4-methoxyphenyl)-piperidin-4-ylmethanone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1CCNCC1 MEKSXLSAYLIUHI-UHFFFAOYSA-N 0.000 claims description 3
- MMGIEYBFDJEQHM-UHFFFAOYSA-N (3,4-dimethylphenyl)-piperidin-4-ylmethanone;hydrochloride Chemical compound Cl.C1=C(C)C(C)=CC=C1C(=O)C1CCNCC1 MMGIEYBFDJEQHM-UHFFFAOYSA-N 0.000 claims description 3
- LZUYKOBTHSPKED-UHFFFAOYSA-N (4-chlorophenyl)-piperidin-4-ylmethanone;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(=O)C1CCNCC1 LZUYKOBTHSPKED-UHFFFAOYSA-N 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 239000012279 sodium borohydride Substances 0.000 claims description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 3
- QNFPAHLLTDNUSX-UHFFFAOYSA-N (4-bromophenyl)-piperidin-4-ylmethanone;hydrochloride Chemical compound Cl.C1=CC(Br)=CC=C1C(=O)C1CCNCC1 QNFPAHLLTDNUSX-UHFFFAOYSA-N 0.000 claims description 2
- AEOMTXRXUAOUEP-UHFFFAOYSA-N 1-(4-benzoylpiperidin-1-yl)-2-(1h-indol-3-yl)ethane-1,2-dione Chemical compound C=1NC2=CC=CC=C2C=1C(=O)C(=O)N(CC1)CCC1C(=O)C1=CC=CC=C1 AEOMTXRXUAOUEP-UHFFFAOYSA-N 0.000 claims description 2
- YUBXEUBNYOBJMQ-UHFFFAOYSA-N 3-(3-bromopropyl)-1h-indole Chemical compound C1=CC=C2C(CCCBr)=CNC2=C1 YUBXEUBNYOBJMQ-UHFFFAOYSA-N 0.000 claims description 2
- UWILYNPREMNRTF-UHFFFAOYSA-N 4-(4-methylphenyl)piperidine Chemical compound C1=CC(C)=CC=C1C1CCNCC1 UWILYNPREMNRTF-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 14
- BURZVPNNFVRUQX-UHFFFAOYSA-N (2-fluorophenyl)-[1-[2-(1h-indol-3-yl)ethyl]piperidin-4-yl]methanone Chemical compound FC1=CC=CC=C1C(=O)C1CCN(CCC=2C3=CC=CC=C3NC=2)CC1 BURZVPNNFVRUQX-UHFFFAOYSA-N 0.000 claims 2
- FNAWTCHCLVACII-UHFFFAOYSA-N (2-hydroxy-4-methoxyphenyl)-[1-[2-(1h-indol-3-yl)ethyl]piperidin-4-yl]methanone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1CCN(CCC=2C3=CC=CC=C3NC=2)CC1 FNAWTCHCLVACII-UHFFFAOYSA-N 0.000 claims 2
- XMHFEFCELCILQJ-UHFFFAOYSA-N (3,4-dimethylphenyl)-[1-[2-(1h-indol-3-yl)ethyl]piperidin-4-yl]methanone Chemical compound C1=C(C)C(C)=CC=C1C(=O)C1CCN(CCC=2C3=CC=CC=C3NC=2)CC1 XMHFEFCELCILQJ-UHFFFAOYSA-N 0.000 claims 2
- LMDSHNVLPOPHLK-UHFFFAOYSA-N (4-bromophenyl)-[1-[2-(1h-indol-3-yl)ethyl]piperidin-4-yl]methanone Chemical compound C1=CC(Br)=CC=C1C(=O)C1CCN(CCC=2C3=CC=CC=C3NC=2)CC1 LMDSHNVLPOPHLK-UHFFFAOYSA-N 0.000 claims 2
- MZXFJZKIGPNQIW-UHFFFAOYSA-N (4-chlorophenyl)-[1-[2-(1h-indol-3-yl)ethyl]piperidin-4-yl]methanone Chemical compound C1=CC(Cl)=CC=C1C(=O)C1CCN(CCC=2C3=CC=CC=C3NC=2)CC1 MZXFJZKIGPNQIW-UHFFFAOYSA-N 0.000 claims 2
- LIPKEWLOECTNQZ-UHFFFAOYSA-N (4-fluorophenyl)-[1-[2-(1h-indol-3-yl)ethyl]piperidin-4-yl]methanol Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1C(O)C1=CC=C(F)C=C1 LIPKEWLOECTNQZ-UHFFFAOYSA-N 0.000 claims 2
- DOINKKIYDOKUAK-UHFFFAOYSA-N (4-fluorophenyl)-[1-[2-(1h-indol-3-yl)ethyl]piperidin-4-yl]methanone;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1C(=O)C1CCN(CCC=2C3=CC=CC=C3NC=2)CC1 DOINKKIYDOKUAK-UHFFFAOYSA-N 0.000 claims 2
- HCYKBRYTXNTNFR-UHFFFAOYSA-N (4-fluorophenyl)-[1-[3-(1h-indol-3-yl)propyl]piperidin-4-yl]methanone;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1C(=O)C1CCN(CCCC=2C3=CC=CC=C3NC=2)CC1 HCYKBRYTXNTNFR-UHFFFAOYSA-N 0.000 claims 2
- GTJNCNPWVQMFAD-UHFFFAOYSA-N [1-[2-(1h-indol-3-yl)ethyl]piperidin-4-yl]-phenylmethanone Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1C(=O)C1=CC=CC=C1 GTJNCNPWVQMFAD-UHFFFAOYSA-N 0.000 claims 2
- 125000003431 oxalo group Chemical group 0.000 claims 2
- ISGDUEADUWXEND-UHFFFAOYSA-N (2-fluoro-4-methylphenyl)-[1-[2-(1h-indol-3-yl)ethyl]piperidin-4-yl]methanone Chemical compound FC1=CC(C)=CC=C1C(=O)C1CCN(CCC=2C3=CC=CC=C3NC=2)CC1 ISGDUEADUWXEND-UHFFFAOYSA-N 0.000 claims 1
- AWJCTVSZKFBTGQ-UHFFFAOYSA-N [1-[2-(1h-indol-3-yl)ethyl]piperidin-4-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)C1CCN(CCC=2C3=CC=CC=C3NC=2)CC1 AWJCTVSZKFBTGQ-UHFFFAOYSA-N 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 abstract description 4
- 230000002936 tranquilizing effect Effects 0.000 abstract description 4
- 230000001760 anti-analgesic effect Effects 0.000 abstract description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 72
- 239000000203 mixture Substances 0.000 description 68
- 239000000243 solution Substances 0.000 description 63
- 239000007787 solid Substances 0.000 description 55
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 53
- 229910052757 nitrogen Inorganic materials 0.000 description 50
- 229910052799 carbon Inorganic materials 0.000 description 45
- 239000003921 oil Substances 0.000 description 33
- 235000019198 oils Nutrition 0.000 description 33
- 238000004458 analytical method Methods 0.000 description 32
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 238000003756 stirring Methods 0.000 description 23
- 239000002244 precipitate Substances 0.000 description 21
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 11
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 11
- OHCPVLJEAHBMEG-UHFFFAOYSA-N 1-acetylpiperidine-4-carbonyl chloride Chemical compound CC(=O)N1CCC(C(Cl)=O)CC1 OHCPVLJEAHBMEG-UHFFFAOYSA-N 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000003610 charcoal Substances 0.000 description 9
- 229910052731 fluorine Inorganic materials 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 5
- 239000012259 ether extract Substances 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000002178 crystalline material Substances 0.000 description 4
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- RJTZUHVCZIGJMB-UHFFFAOYSA-N hydron;1h-indole;chloride Chemical compound Cl.C1=CC=C2NC=CC2=C1 RJTZUHVCZIGJMB-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 150000003891 oxalate salts Chemical class 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- WFCLWJHOKCQYOQ-UHFFFAOYSA-N 1-acetylpiperidine-4-carboxylic acid Chemical compound CC(=O)N1CCC(C(O)=O)CC1 WFCLWJHOKCQYOQ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- SLUNEGLMXGHOLY-UHFFFAOYSA-N benzene;hexane Chemical compound CCCCCC.C1=CC=CC=C1 SLUNEGLMXGHOLY-UHFFFAOYSA-N 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- RCYQTTNQDIKOBZ-UHFFFAOYSA-N piperidin-4-yl-[3-(trifluoromethyl)phenyl]methanone Chemical group FC(F)(F)C1=CC=CC(C(=O)C2CCNCC2)=C1 RCYQTTNQDIKOBZ-UHFFFAOYSA-N 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- YWAPYOZVWDULDD-UHFFFAOYSA-N (2,4-dimethoxyphenyl)-piperidin-4-ylmethanone;hydrochloride Chemical compound Cl.COC1=CC(OC)=CC=C1C(=O)C1CCNCC1 YWAPYOZVWDULDD-UHFFFAOYSA-N 0.000 description 2
- XMAQOPAESWRHAY-UHFFFAOYSA-N (2-hydroxyphenyl)-piperidin-4-ylmethanone Chemical class OC1=CC=CC=C1C(=O)C1CCNCC1 XMAQOPAESWRHAY-UHFFFAOYSA-N 0.000 description 2
- ZUOIHUYQCDKTDH-UHFFFAOYSA-N (4-hydroxyphenyl)-piperidin-4-ylmethanone;hydrobromide Chemical compound Br.C1=CC(O)=CC=C1C(=O)C1CCNCC1 ZUOIHUYQCDKTDH-UHFFFAOYSA-N 0.000 description 2
- MEAYERISLPBAKL-UHFFFAOYSA-N (4-phenylphenyl)-piperidin-4-ylmethanone Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(=O)C1CCNCC1 MEAYERISLPBAKL-UHFFFAOYSA-N 0.000 description 2
- KUWXBTTYRJFQOJ-UHFFFAOYSA-N (4-tert-butylphenyl)-piperidin-4-ylmethanone;hydrochloride Chemical compound Cl.C1=CC(C(C)(C)C)=CC=C1C(=O)C1CCNCC1 KUWXBTTYRJFQOJ-UHFFFAOYSA-N 0.000 description 2
- DPZNOMCNRMUKPS-UHFFFAOYSA-N 1,3-Dimethoxybenzene Chemical compound COC1=CC=CC(OC)=C1 DPZNOMCNRMUKPS-UHFFFAOYSA-N 0.000 description 2
- AXPZSNWFBZMANU-UHFFFAOYSA-N 1-(4-benzoylpiperidin-1-yl)-2-(5,6-dimethoxy-2-methyl-1h-indol-3-yl)ethane-1,2-dione Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(C)=C1C(=O)C(=O)N(CC1)CCC1C(=O)C1=CC=CC=C1 AXPZSNWFBZMANU-UHFFFAOYSA-N 0.000 description 2
- VRURKQHXOIXKQK-UHFFFAOYSA-N 1-[4-(2-fluoro-4-methylbenzoyl)piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1C(=O)C1=CC=C(C)C=C1F VRURKQHXOIXKQK-UHFFFAOYSA-N 0.000 description 2
- YIELGQWFNQRQGV-UHFFFAOYSA-N 1-[4-(2-hydroxy-4-methoxybenzoyl)piperidin-1-yl]ethanone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1CCN(C(C)=O)CC1 YIELGQWFNQRQGV-UHFFFAOYSA-N 0.000 description 2
- HDJWXHJXCUXKLU-UHFFFAOYSA-N 1-[4-(3,4-dimethylbenzoyl)piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1C(=O)C1=CC=C(C)C(C)=C1 HDJWXHJXCUXKLU-UHFFFAOYSA-N 0.000 description 2
- OWZNKBHPOLNFOG-UHFFFAOYSA-N 1-[4-(4-bromobenzoyl)piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1C(=O)C1=CC=C(Br)C=C1 OWZNKBHPOLNFOG-UHFFFAOYSA-N 0.000 description 2
- SJFAMZWCYIGDBM-UHFFFAOYSA-N 1-[4-(4-phenoxybenzoyl)piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1C(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 SJFAMZWCYIGDBM-UHFFFAOYSA-N 0.000 description 2
- BAPGRKXCVFPBLF-UHFFFAOYSA-N 1-[4-(4-tert-butylbenzoyl)piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1C(=O)C1=CC=C(C(C)(C)C)C=C1 BAPGRKXCVFPBLF-UHFFFAOYSA-N 0.000 description 2
- YXTROGRGRSPWKL-UHFFFAOYSA-N 1-benzoylpiperidine Chemical compound C=1C=CC=CC=1C(=O)N1CCCCC1 YXTROGRGRSPWKL-UHFFFAOYSA-N 0.000 description 2
- ZOBKIUOQZMGNKB-UHFFFAOYSA-N 1-methyl-4-(3-methylphenyl)piperidine Chemical compound C1CN(C)CCC1C1=CC=CC(C)=C1 ZOBKIUOQZMGNKB-UHFFFAOYSA-N 0.000 description 2
- XDKIJVHMXVWURI-UHFFFAOYSA-N 2-(5,6-dimethoxy-2-methyl-1h-indol-3-yl)-2-oxoacetyl chloride Chemical compound C1=C(OC)C(OC)=CC2=C1C(C(=O)C(Cl)=O)=C(C)N2 XDKIJVHMXVWURI-UHFFFAOYSA-N 0.000 description 2
- UJEPFWNSLTXXGP-UHFFFAOYSA-N 4-(2-methylphenyl)piperidine;hydrochloride Chemical compound Cl.CC1=CC=CC=C1C1CCNCC1 UJEPFWNSLTXXGP-UHFFFAOYSA-N 0.000 description 2
- ZVKQARCPEZNELE-UHFFFAOYSA-N 4-(3-methylphenyl)piperidine;hydrochloride Chemical compound Cl.CC1=CC=CC(C2CCNCC2)=C1 ZVKQARCPEZNELE-UHFFFAOYSA-N 0.000 description 2
- ROPXDRJXVYKIPI-UHFFFAOYSA-N 4-(4-methylphenyl)piperidine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C1CCNCC1 ROPXDRJXVYKIPI-UHFFFAOYSA-N 0.000 description 2
- MYGXGCCFTPKWIH-UHFFFAOYSA-N 4-chloro-1-methylpiperidine Chemical compound CN1CCC(Cl)CC1 MYGXGCCFTPKWIH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical class ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- RYZCLUQMCYZBJQ-UHFFFAOYSA-H lead(2+);dicarbonate;dihydroxide Chemical compound [OH-].[OH-].[Pb+2].[Pb+2].[Pb+2].[O-]C([O-])=O.[O-]C([O-])=O RYZCLUQMCYZBJQ-UHFFFAOYSA-H 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- JGKKVWRXPGZBKN-UHFFFAOYSA-N phenyl 4-(2-fluorobenzoyl)piperidine-1-carboxylate Chemical compound FC1=CC=CC=C1C(=O)C1CCN(C(=O)OC=2C=CC=CC=2)CC1 JGKKVWRXPGZBKN-UHFFFAOYSA-N 0.000 description 2
- AHUMNHRMBJLNIB-UHFFFAOYSA-N phenyl 4-(3-methylphenyl)piperidine-1-carboxylate Chemical compound CC1=CC=CC(C2CCN(CC2)C(=O)OC=2C=CC=CC=2)=C1 AHUMNHRMBJLNIB-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 238000012289 standard assay Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 239000003204 tranquilizing agent Substances 0.000 description 2
- RPLQRYXJBIJBFR-UHFFFAOYSA-N (1-methylpiperidin-4-yl)-phenylmethanone Chemical compound C1CN(C)CCC1C(=O)C1=CC=CC=C1 RPLQRYXJBIJBFR-UHFFFAOYSA-N 0.000 description 1
- MSCURGXTUQIQQN-UHFFFAOYSA-N (2-fluorophenyl)-(1-methylpiperidin-4-yl)methanone Chemical compound C1CN(C)CCC1C(=O)C1=CC=CC=C1F MSCURGXTUQIQQN-UHFFFAOYSA-N 0.000 description 1
- LLHFDMUWLLHBQW-UHFFFAOYSA-N (3-fluorophenyl)-piperidin-4-ylmethanone Chemical compound FC1=CC=CC(C(=O)C2CCNCC2)=C1 LLHFDMUWLLHBQW-UHFFFAOYSA-N 0.000 description 1
- ZYKYHSIACDLOCE-UHFFFAOYSA-N (4-methoxyphenyl)-piperidin-4-ylmethanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCNCC1 ZYKYHSIACDLOCE-UHFFFAOYSA-N 0.000 description 1
- BBDTWYQCXXFKDH-UHFFFAOYSA-N (4-methoxyphenyl)-piperidin-4-ylmethanone;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C(=O)C1CCNCC1 BBDTWYQCXXFKDH-UHFFFAOYSA-N 0.000 description 1
- JHCCIMAETDJFSC-UHFFFAOYSA-N (4-phenoxyphenyl)-piperidin-4-ylmethanone;hydrochloride Chemical compound Cl.C=1C=C(OC=2C=CC=CC=2)C=CC=1C(=O)C1CCNCC1 JHCCIMAETDJFSC-UHFFFAOYSA-N 0.000 description 1
- XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- YAXJUSWPGTYBSM-UHFFFAOYSA-N 1-(1h-indol-2-yl)-2-piperidin-1-ylethane-1,2-dione Chemical class C=1C2=CC=CC=C2NC=1C(=O)C(=O)N1CCCCC1 YAXJUSWPGTYBSM-UHFFFAOYSA-N 0.000 description 1
- RZQPAQOFGPUUOC-UHFFFAOYSA-N 1-(1h-indol-3-yl)-2-piperidin-1-ylethane-1,2-dione Chemical compound C=1NC2=CC=CC=C2C=1C(=O)C(=O)N1CCCCC1 RZQPAQOFGPUUOC-UHFFFAOYSA-N 0.000 description 1
- AVUUDBGJLILUPD-UHFFFAOYSA-N 1-[4-(2,4-dimethoxybenzoyl)piperidin-1-yl]ethanone Chemical compound COC1=CC(OC)=CC=C1C(=O)C1CCN(C(C)=O)CC1 AVUUDBGJLILUPD-UHFFFAOYSA-N 0.000 description 1
- JCGSSOIJYPBNJE-UHFFFAOYSA-N 1-[4-(4-fluorobenzoyl)piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1C(=O)C1=CC=C(F)C=C1 JCGSSOIJYPBNJE-UHFFFAOYSA-N 0.000 description 1
- NPPKZDZNXIHDQS-UHFFFAOYSA-N 1-[4-(4-methoxybenzoyl)piperidin-1-yl]ethanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(C)=O)CC1 NPPKZDZNXIHDQS-UHFFFAOYSA-N 0.000 description 1
- NFDGRMQIOHRQHF-UHFFFAOYSA-N 1-acetylpiperidine-4-carbonitrile Chemical compound CC(=O)N1CCC(C#N)CC1 NFDGRMQIOHRQHF-UHFFFAOYSA-N 0.000 description 1
- NWZYRRPOEASODK-UHFFFAOYSA-N 1-acetylpiperidine-4-carboxamide Chemical compound CC(=O)N1CCC(C(N)=O)CC1 NWZYRRPOEASODK-UHFFFAOYSA-N 0.000 description 1
- NNMBNYHMJRJUBC-UHFFFAOYSA-N 1-bromo-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(Br)=C1 NNMBNYHMJRJUBC-UHFFFAOYSA-N 0.000 description 1
- BTQZKHUEUDPRST-UHFFFAOYSA-N 1-fluoro-3-methylbenzene Chemical compound CC1=CC=CC(F)=C1 BTQZKHUEUDPRST-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- FPEGGKCNMYDNMW-UHFFFAOYSA-N 2-(1h-indol-3-yl)-2-oxoacetyl chloride Chemical compound C1=CC=C2C(C(=O)C(=O)Cl)=CNC2=C1 FPEGGKCNMYDNMW-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- GDHXJNRAJRCGMX-UHFFFAOYSA-N 2-fluorobenzonitrile Chemical compound FC1=CC=CC=C1C#N GDHXJNRAJRCGMX-UHFFFAOYSA-N 0.000 description 1
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- UJFNVVLLJVRINU-UHFFFAOYSA-N 3-(3-bromopropyl)-6-methoxy-2-methyl-1h-indole Chemical compound COC1=CC=C2C(CCCBr)=C(C)NC2=C1 UJFNVVLLJVRINU-UHFFFAOYSA-N 0.000 description 1
- ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- IFRIJXPBIJQSSL-UHFFFAOYSA-N 4-[[[3-(4-fluorophenyl)-3-(furan-2-yl)propyl]amino]methyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1CNCCC(C=1C=CC(F)=CC=1)C1=CC=CO1 IFRIJXPBIJQSSL-UHFFFAOYSA-N 0.000 description 1
- ZMMVNMYKBFCJDA-UHFFFAOYSA-N 5,6-dimethoxy-2-methyl-1h-indole Chemical compound C1=C(OC)C(OC)=CC2=C1NC(C)=C2 ZMMVNMYKBFCJDA-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- VGHOWOWLIXPTOA-UHFFFAOYSA-N cyclohexane;toluene Chemical compound C1CCCCC1.CC1=CC=CC=C1 VGHOWOWLIXPTOA-UHFFFAOYSA-N 0.000 description 1
- 230000020335 dealkylation Effects 0.000 description 1
- 238000006900 dealkylation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- YKWNUSJLICDQEO-UHFFFAOYSA-N ethoxyethane;propan-2-ol Chemical compound CC(C)O.CCOCC YKWNUSJLICDQEO-UHFFFAOYSA-N 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 150000002238 fumaric acids Chemical class 0.000 description 1
- NLZGZUVTOHQCQF-UHFFFAOYSA-N furan-2-yl(thiomorpholin-4-yl)methanone Chemical compound C=1C=COC=1C(=O)N1CCSCC1 NLZGZUVTOHQCQF-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- NWPNXBQSRGKSJB-UHFFFAOYSA-N o-methylbenzonitrile Natural products CC1=CC=CC=C1C#N NWPNXBQSRGKSJB-UHFFFAOYSA-N 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 150000002913 oxalic acids Chemical class 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- NXYKIFZJQXOUJS-UHFFFAOYSA-N phenyl(piperidin-1-ium-4-yl)methanone;chloride Chemical compound Cl.C=1C=CC=CC=1C(=O)C1CCNCC1 NXYKIFZJQXOUJS-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- SAALQYKUFCIMHR-UHFFFAOYSA-N propan-2-ol;2-propan-2-yloxypropane Chemical compound CC(C)O.CC(C)OC(C)C SAALQYKUFCIMHR-UHFFFAOYSA-N 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- OENLEHTYJXMVBG-UHFFFAOYSA-N pyridine;hydrate Chemical compound [OH-].C1=CC=[NH+]C=C1 OENLEHTYJXMVBG-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003444 succinic acids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
BENZOYLPIPERIDYLALKYLINDOLES AND RELATED COMPOUNDS
Abstract of the Disclosure:
New benzoylpiperidylalkylindoles and related compounds possessing tranquilizing, anti-hypertensive and analgesic properties and a process for the preparation thereof.
Abstract of the Disclosure:
New benzoylpiperidylalkylindoles and related compounds possessing tranquilizing, anti-hypertensive and analgesic properties and a process for the preparation thereof.
Description
; :
la7~3~7 This invention relates to benzoylpiperidylalkylindoles and related compounds possessing tranquilizing properties and to a process for the preparation thereof. Additionally, some compounds of the invention also demonstrate anti-hypertensive and analgesic properties.
To the best of our knowledge, the compounds of the present invention have not heretofore been described.
Indoles exhibiting action on the cardiovascular system are mentioned in United States Patent 3,527,761 (1970). United States Patents 3,188,313 (1965) and 3,217,011 (1965) ' describe 1-(1,2 and 3-indolyl)-lower piperazine derivatives and 1-(indolylglyoxalyl)piperidines, respectively as having important biological activity. Additionally, United States Patent 3,821,387 (1974) describes 3-(omega-substituted alkyl)-indoles as being useful in the treatment of Parkinsonism.
However, the compounds of the present invention have substantial structural differences with respect to the prior art.
The compounds of the invention conform to the general formula CH~)n-~2- \ ~ ( ~ R
4 H :~
~J :.
.. .. .
` HOE 76/F 249 iO7t~3~7 wherein X is C=O or CHOH; R is hydrogen or methyl; R1 and R2 are the same or different and stand for hydrogen, halogen, straight or branched chain alkyl of up to 5 carbon atoms, alkoxy of up to 5 carbon atoms, trifluoromethyl, hydroxy, phenoxy or phenyl; R3 and R4 are hydrogen or methoxy; n is the integer 1 or 2; and the acid addition salts thereof prepare from pharmaceutically acceptable acids.
Acids useful for preparing the acid addition salts of the invention include inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric and perchloric acids, as well as organic acids such as tartaric, citric, acetic, succinic, maleic, fumaric and oxalic acids.
The compounds of the invention are prepared by either of the two sequences of reactions described below wherein R, R1, R2, R3, R4 and n are as defined earlier. The starting compounds, the 4~xnzoyl-piperidines, are prepared from N-acetylisonipecotic acid or from 1-acetylisonipecotamide by the methods described by Robert L. Duncan, Jr. et al., J. Med. Chem. 1, 1, (1970~.
The 4-(hydroxybenzoyl)piperidines are prepared by a somewhat different method. The N-acetyli~nipecotic acid chloride is reacted with an alkoxy substituted benzene under Friedel-Crafts condition to give a 1-acetyl-4-(alkoxybenzoyl)-piperidine. The reaction of this piperidine with hydrogen bromide produces hydrolysis of the acetyl group and dealkylation of the alkoxy group, giving a corresponding 4-(hydroxybenzoyl)piperidine.
Additionally, a benzoylpiperidine can be prepared ` by the three step method outlined below.
, :. : ", : , ~78387 1. A 4-benzoyl-1-methylpiperidine is produced by the reaction of a benzonitrile of the formula NC~
1`2 with a Grignard reagent prepared from N-methyl-4-chloropiperidine at a temperature of from 15 C.to the boiling point of the solvent, if any, for from 1 to 15 hours. One preferred method utilizers tetrahydrofuran as the solvent and allows the mixture to react at reflux for 2 hours and then at ambient temperature overnight.
la7~3~7 This invention relates to benzoylpiperidylalkylindoles and related compounds possessing tranquilizing properties and to a process for the preparation thereof. Additionally, some compounds of the invention also demonstrate anti-hypertensive and analgesic properties.
To the best of our knowledge, the compounds of the present invention have not heretofore been described.
Indoles exhibiting action on the cardiovascular system are mentioned in United States Patent 3,527,761 (1970). United States Patents 3,188,313 (1965) and 3,217,011 (1965) ' describe 1-(1,2 and 3-indolyl)-lower piperazine derivatives and 1-(indolylglyoxalyl)piperidines, respectively as having important biological activity. Additionally, United States Patent 3,821,387 (1974) describes 3-(omega-substituted alkyl)-indoles as being useful in the treatment of Parkinsonism.
However, the compounds of the present invention have substantial structural differences with respect to the prior art.
The compounds of the invention conform to the general formula CH~)n-~2- \ ~ ( ~ R
4 H :~
~J :.
.. .. .
` HOE 76/F 249 iO7t~3~7 wherein X is C=O or CHOH; R is hydrogen or methyl; R1 and R2 are the same or different and stand for hydrogen, halogen, straight or branched chain alkyl of up to 5 carbon atoms, alkoxy of up to 5 carbon atoms, trifluoromethyl, hydroxy, phenoxy or phenyl; R3 and R4 are hydrogen or methoxy; n is the integer 1 or 2; and the acid addition salts thereof prepare from pharmaceutically acceptable acids.
Acids useful for preparing the acid addition salts of the invention include inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric and perchloric acids, as well as organic acids such as tartaric, citric, acetic, succinic, maleic, fumaric and oxalic acids.
The compounds of the invention are prepared by either of the two sequences of reactions described below wherein R, R1, R2, R3, R4 and n are as defined earlier. The starting compounds, the 4~xnzoyl-piperidines, are prepared from N-acetylisonipecotic acid or from 1-acetylisonipecotamide by the methods described by Robert L. Duncan, Jr. et al., J. Med. Chem. 1, 1, (1970~.
The 4-(hydroxybenzoyl)piperidines are prepared by a somewhat different method. The N-acetyli~nipecotic acid chloride is reacted with an alkoxy substituted benzene under Friedel-Crafts condition to give a 1-acetyl-4-(alkoxybenzoyl)-piperidine. The reaction of this piperidine with hydrogen bromide produces hydrolysis of the acetyl group and dealkylation of the alkoxy group, giving a corresponding 4-(hydroxybenzoyl)piperidine.
Additionally, a benzoylpiperidine can be prepared ` by the three step method outlined below.
, :. : ", : , ~78387 1. A 4-benzoyl-1-methylpiperidine is produced by the reaction of a benzonitrile of the formula NC~
1`2 with a Grignard reagent prepared from N-methyl-4-chloropiperidine at a temperature of from 15 C.to the boiling point of the solvent, if any, for from 1 to 15 hours. One preferred method utilizers tetrahydrofuran as the solvent and allows the mixture to react at reflux for 2 hours and then at ambient temperature overnight.
2. The reaction of an above piperidine with a substituted chloroformate such as phenylchloroformate or an alkylchloroformate in the presence of an organic solvent such as methylene chloride or toluene at a temperature of from ambient to the boiling point of the solvent for from a few minutes to 12 hours produces N-carbonyl compound of the formula O ~ ~ O; ~ R
wherein Y is phenyl or alkyl. A preferred chloroformate is phenylchloroformate.
wherein Y is phenyl or alkyl. A preferred chloroformate is phenylchloroformate.
3. A benzoylpiperidine is prepared by cleaving the carbonal moiety from the above N-carbonyl compound. A
preferred method of cleaving is carried out by dissolving an N-carbonyl compound in an aqueous solution of 30 - 50 %
potassium hydroxide and an organic solvent such as ethanol ~. :
and permitting the solution to react at a temperature of from ambient to the boiling point of the solvent for from 1 hour to 60 hours.
METHOD I
A. A sample of 3~ bromoalkyl)indole is reacted with a 4-benzoylpiperidine of the formula ~ ,~ ';1 in the presence of a suitable organic solvent such as dimethylformamide, n-butanol, or dimethylsulfoxide, with or without an acid scavenger such as potassium carbonate, triethylamine or sodium bicarbonate, at a temperature of from about 20 C to the boiling point of the solvent for from 30 minutes to 120 hours to give a compound of the invention of the formula U ~ C 2) -C~2-N ~ C~ ]
preferred method of cleaving is carried out by dissolving an N-carbonyl compound in an aqueous solution of 30 - 50 %
potassium hydroxide and an organic solvent such as ethanol ~. :
and permitting the solution to react at a temperature of from ambient to the boiling point of the solvent for from 1 hour to 60 hours.
METHOD I
A. A sample of 3~ bromoalkyl)indole is reacted with a 4-benzoylpiperidine of the formula ~ ,~ ';1 in the presence of a suitable organic solvent such as dimethylformamide, n-butanol, or dimethylsulfoxide, with or without an acid scavenger such as potassium carbonate, triethylamine or sodium bicarbonate, at a temperature of from about 20 C to the boiling point of the solvent for from 30 minutes to 120 hours to give a compound of the invention of the formula U ~ C 2) -C~2-N ~ C~ ]
4 ll B. These benzoylpiperidylalkylindoles can be reduced to give a compound of the invention of the formula ~ ~ ~~ ) ()H ~ R
In one preferred method, sodium borohydride is utilized as ~' the reducing agent.
.
1C~7838~
, METHOD II
A. A sample of an indole of the formula -~
E3 - k~l ~ R
in a solvent such as anhydrous ether is allowed to react with oxalyl chloride at a temperature of from -15 to 15 C
for from a couple of minutes to one hour to produce a mixture of a corresponding 3-indoleglyoxyloyl chloride in the solvent which is then added to a cooled solution of 4-benzoylpiperidine in a suitable organic solvent such as chloroform optionally containing an acid scavenger such as potassium carbonate and allowing the mixture to react at a temperature of from 15 to 40C for a few minutes to 12 hours to produce a 4-benzoyl-1-(indol-3-ylglyoxyloyl)piperidine of the formula ~ ~ - C -N ~ - C - ~ 1 B. An above (indol-3-ylglyoxyloyl)piperidine is reduced to produce an arylhydroxymethylpiperidylethylindole a compound of the invention of the formula illustrated in Method I, step B in which n is 1. A preferred method utilizes lithium aluminum hydride as the reducing agent, tetrahydrofuran as a solvent, the boiling point of the solvent as the reaction temperature and a reaction time of from a few minutes to 5 hours.
The compounds of the invention are useful as tranquilizers due to their depressant action on the central nervous system 10783~7 HOE 76/F 249 of mammals. This activity is demonstrated in the mouse observation procedure, a standard assay for central nervous system depressants (Psychopharmacologia, 9, 259 (1966). Thus~
for example, the minimum effective dose (MED) at which 3- ~3-L4 - ( 4-fluorobenzoyl)piperidylJpropyl~indole hydrochloride displays significant effects on behavior and reflex depression together with musele relaxation is 1 mg/kg of body weight. Similarly, MED's of other compounds are:
Compound MED
m 10 3-~2-~4-(4-fluorobenzoyl)piperidyl3ethyl~- 10 indole 3-[2-(4-benzoylpiperidyl)ethylJindole20 3-~2- L4 - ( 4-toluyl)piperidyl3ethy~ indole 40 Some compounds of the invention are also useful as anti-hypertensive agents due to their ability to depress blood pressure in mammals. Anti-hypertensive activity is measured in the spontaneous hypertensive rate by the indirect tail cuff method described in A. Schwartz, Ed., Methods in Pharmacology, Vol. I, page 135, Appleton-Century-Crofts, New York, New York 1971. In this procedure a group of five animals are dosed orally with 100 mg of the compound per kg of body weight in relating to a control group of the same number. The antihypertensive activity in this test of some of the compounds of the invention is illustrated in Table I. -TABLE I
Compound Day 1 Day 3 mmHg mmHg 3-~2-(4-benzoylpiperidyl)ethyl~indole -53.8 -79.7 3-~2- t4 - ( 4-toluyl)piperidyl~ethyl~indole -63.6 -61.0 3-~2-L4-(4-~hlorobenzoyl)piperidyl~ ethyl~ indole -39.0 -67.8 3-~2-L4-(4-bromobenzoyl)piperidyl~ethyl~indole -15.8 -57.2 ~783~7 HOE 76/F 249 Compounds of the invention are useful as analgesic agents due to their ability to alleviate pain in mammals.
The activity of the compounds is demonstrated in the 2-phenyl-1,4-benzoquinone-induced writhing test in mice, a standard assay for analgesia (Proc. Soc. Exptl. Biol. Med., 95, 79 (1957)). For example at doses of 4.4, 11, 15, 20 and 35 mg/kg of body weight, 3-~3-~4-(4-fluorobenzoyl)piperidyl~propyl~-indole hydrochloride, 3-~2-L4-(4-toluyl~piperidylJethyl~indole, 3-~2- L4 - ( 4-fluorobenzoyl)piperidyl~ethyl~indole hydrochloride~
3-L2-(4-benzoylpiperidyl)ethyl~indole, and 3-~2-t4-(4-chloro-benzoyl)piperidine]ethyl~indole, respectively, exhibit an approximately 50 ~ inhibition of writhing.
The above date illustrates that the compounds of the present invention are useful as tranquilizers and for the treatment of hypertension and alleviation of pain when administered to mammals at doses of from 0.1 to 100 mg/kg.
Examples of the compounds of the invention are: `
3-~2-C4-(4-hydroxybenzoyl)piperidyl~ethyl~indole;
3-{2-L4-(4-ethylbenzoyl)piperidylJethyl~indole;
3-{2-~4-(4-_-butylbenzoyl)piperidyl3ethyl~indole;
3-{2-[4-(4-ethoxybenzoyl)piperidyl~ethyl~indole;
3-~2-[4-(4-trifluoromethylbenzoyl)piperidyl~ ethylJindole;
3-{2-~4-(2-bromo-4-ethylbenzoyl)piperidylJethyl~indole;
3-~2-~4-(3,4-dichlorobenzoyl)piperidylJethyl3indole;
3-~2-~4-(4-chlorophenylhydroxymethyl)piperidylJethyl~-indole;
3-~2-~4-t4-isopropylphenylhydroxymethyl)piperidylJethyl~ -indole;
.. :: : .. : . .
~783~7 HOE 76/F 249
In one preferred method, sodium borohydride is utilized as ~' the reducing agent.
.
1C~7838~
, METHOD II
A. A sample of an indole of the formula -~
E3 - k~l ~ R
in a solvent such as anhydrous ether is allowed to react with oxalyl chloride at a temperature of from -15 to 15 C
for from a couple of minutes to one hour to produce a mixture of a corresponding 3-indoleglyoxyloyl chloride in the solvent which is then added to a cooled solution of 4-benzoylpiperidine in a suitable organic solvent such as chloroform optionally containing an acid scavenger such as potassium carbonate and allowing the mixture to react at a temperature of from 15 to 40C for a few minutes to 12 hours to produce a 4-benzoyl-1-(indol-3-ylglyoxyloyl)piperidine of the formula ~ ~ - C -N ~ - C - ~ 1 B. An above (indol-3-ylglyoxyloyl)piperidine is reduced to produce an arylhydroxymethylpiperidylethylindole a compound of the invention of the formula illustrated in Method I, step B in which n is 1. A preferred method utilizes lithium aluminum hydride as the reducing agent, tetrahydrofuran as a solvent, the boiling point of the solvent as the reaction temperature and a reaction time of from a few minutes to 5 hours.
The compounds of the invention are useful as tranquilizers due to their depressant action on the central nervous system 10783~7 HOE 76/F 249 of mammals. This activity is demonstrated in the mouse observation procedure, a standard assay for central nervous system depressants (Psychopharmacologia, 9, 259 (1966). Thus~
for example, the minimum effective dose (MED) at which 3- ~3-L4 - ( 4-fluorobenzoyl)piperidylJpropyl~indole hydrochloride displays significant effects on behavior and reflex depression together with musele relaxation is 1 mg/kg of body weight. Similarly, MED's of other compounds are:
Compound MED
m 10 3-~2-~4-(4-fluorobenzoyl)piperidyl3ethyl~- 10 indole 3-[2-(4-benzoylpiperidyl)ethylJindole20 3-~2- L4 - ( 4-toluyl)piperidyl3ethy~ indole 40 Some compounds of the invention are also useful as anti-hypertensive agents due to their ability to depress blood pressure in mammals. Anti-hypertensive activity is measured in the spontaneous hypertensive rate by the indirect tail cuff method described in A. Schwartz, Ed., Methods in Pharmacology, Vol. I, page 135, Appleton-Century-Crofts, New York, New York 1971. In this procedure a group of five animals are dosed orally with 100 mg of the compound per kg of body weight in relating to a control group of the same number. The antihypertensive activity in this test of some of the compounds of the invention is illustrated in Table I. -TABLE I
Compound Day 1 Day 3 mmHg mmHg 3-~2-(4-benzoylpiperidyl)ethyl~indole -53.8 -79.7 3-~2- t4 - ( 4-toluyl)piperidyl~ethyl~indole -63.6 -61.0 3-~2-L4-(4-~hlorobenzoyl)piperidyl~ ethyl~ indole -39.0 -67.8 3-~2-L4-(4-bromobenzoyl)piperidyl~ethyl~indole -15.8 -57.2 ~783~7 HOE 76/F 249 Compounds of the invention are useful as analgesic agents due to their ability to alleviate pain in mammals.
The activity of the compounds is demonstrated in the 2-phenyl-1,4-benzoquinone-induced writhing test in mice, a standard assay for analgesia (Proc. Soc. Exptl. Biol. Med., 95, 79 (1957)). For example at doses of 4.4, 11, 15, 20 and 35 mg/kg of body weight, 3-~3-~4-(4-fluorobenzoyl)piperidyl~propyl~-indole hydrochloride, 3-~2-L4-(4-toluyl~piperidylJethyl~indole, 3-~2- L4 - ( 4-fluorobenzoyl)piperidyl~ethyl~indole hydrochloride~
3-L2-(4-benzoylpiperidyl)ethyl~indole, and 3-~2-t4-(4-chloro-benzoyl)piperidine]ethyl~indole, respectively, exhibit an approximately 50 ~ inhibition of writhing.
The above date illustrates that the compounds of the present invention are useful as tranquilizers and for the treatment of hypertension and alleviation of pain when administered to mammals at doses of from 0.1 to 100 mg/kg.
Examples of the compounds of the invention are: `
3-~2-C4-(4-hydroxybenzoyl)piperidyl~ethyl~indole;
3-{2-L4-(4-ethylbenzoyl)piperidylJethyl~indole;
3-{2-~4-(4-_-butylbenzoyl)piperidyl3ethyl~indole;
3-{2-[4-(4-ethoxybenzoyl)piperidyl~ethyl~indole;
3-~2-[4-(4-trifluoromethylbenzoyl)piperidyl~ ethylJindole;
3-{2-~4-(2-bromo-4-ethylbenzoyl)piperidylJethyl~indole;
3-~2-~4-(3,4-dichlorobenzoyl)piperidylJethyl3indole;
3-~2-~4-(4-chlorophenylhydroxymethyl)piperidylJethyl~-indole;
3-~2-~4-t4-isopropylphenylhydroxymethyl)piperidylJethyl~ -indole;
.. :: : .. : . .
~783~7 HOE 76/F 249
5-methoxy-3-{3-L4-(3-methoxybenzoyl)piperidyl~propyl~-indole; and 5,6-dimethoxy-2-methyl-3-~3-~4-(4-trifluoromethylphenyl-hydroxymethyl)piperidyl3propyl~indole.
The compounds of the present invention may be administered to a patient by a convenient route such as orally, intramuscu-larly, intraveneously, subcutaneously or intraperitoneally. The preferred route of administration is oral, for example, with an inert diluent or with an edible carrier or in gelatin capsules or tablets.
For the purpose of oral therapeutic administration, the active compounds of this invention may be incorporated with excipients and used in the form of tablets, troches, capsules elixirs, suspensions, syrups, wafers, chewing gum, and the like. These preparations should cont~in at least 0.5 % of active compound, but may be varied depending upon the particular form and may conveniently be between 7 % to about 70 % by weight of the unit. The amount of active compound in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form contains between 1 and 200 milligrams of active compound.
The tablets, pills, capsules, troches, and the like may also contain the following ingredients: a binder such as gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, potato starch and the like; a lubricant such as magnesium stearate;
~ and a sweetening agent such as sucrose or saccharin may be - . . ... . .. .. ., , . , ~ . -, , . - . . -., ~. : :: .i, .......... ,.. .. - ~ .... .. : . .
~,: , ' ' :
1~78387 HOE 76/F 249 added or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil. Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings.
Thus, tablets or pills may be coated with sugar, shellac, or both. A syrup may contain, in addition to the active compounds sucrose as a sweetening agent, and certain preservatives, dyes and colorings, and flavors. Materials used in preparing these various compositions must be pharmaceutically pure and non-toxic in the amounts utilized.
For the purpose of parenteral therapeutics administration, the active compounds of the invention may be incorporated into a solution of suspension. These preparations should con-tain at least 0.1 % of active compound, but may be varied to be between 0.5 and about 30 ~ of the weight thereof. The amount of active compound in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 0.5 to 100 milligrams of active compound.
The solutions or suspensions may also include the follo-wing components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol ~ methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as : : .~" :: .: , :.: ~ .-10783~7 HOE 76/F 249 acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
The parenteral preparation can be enclosed in ampules, disposable syringes or muItiple dose vials made of glass or plastic.
The invention is further illustrated by the following examples given for illustrative purposes.
E X A M P L E
A. A solution of 51.6 g of isonipecotic acid in 200 ml of acetic anhydride is refluxed for 2 hours and allowed to stir at ambient temperature for 16 hours. The solution is concentrated and the resulting residue is triturated in ether.
The solid is collected by filtration and recrystallized from an isopropyl alcohol-diisopropyl ether mixture giving 1-acetyl-isonipecotic acid as a white solid.
B. ~ sample of 65.4 g of 1-acetylisonipecotic acid is dissolved in 400 ml of thionyl chloride. The acid chloride precipitates from solution and one liter of petroleum ether is added. The mixture is filtered, the solid residue is washed several times with petroleum ether and dried, giving 1-acetyl-isonipecotoyl chloride as a white solid.
C. 70 g of 1-acetylisonipecotoyl chloride are slowly added to a stirring mixture of 93.0 g of aluminum chloride in 150 ml of fluorobenzene. After total addition, the mixture is *
poured onto ice and the two resulting layers separate. The aqueous layer is extracted twice with chloroform and the extracts are added to the fluorobenzene which separated previous-ly. The organic solution is dried and concentrated under " reduced pressure leaving a crystalline white solid. The solid *) refluxsd for one hour. The mixture is ., , ' ' . . ~ ' ' ,', . ` I ! ' ' '~, , ', .' ' '.'" "' ' ". ''' '' : ` ' ': '."' ' :. ' . ' ''" ~
~0783~ 7 HOE 76/F 249 is recrystalli~ed from a ligroin-diisopropyl ether mixture, producing 1-acetyl-4-(4-fluoro-benz~l)piperidine.
D. A solution of 70.6 g of 1-acetyl-4-(4-fluorobenzoyl)-piperidine in 200 ml of 6N HCl is refluxed for 2 hours. The cooled solution is extracted twice with ether, the aqueous solution basified with sodium hydroxide and then extracted with benzene. The benzene extracts are dried, filtered and the filtrate is concentrated under reduced pressure. The residual oil is dissolved in ether and HCl gas is bubbled into the solution with stirring. The salt is collected by filtration5 washed with ether and dried. The salt is recrystallized from isopropanol to give the solid product of 4-(4-fluorobenzoyl)-piperidine hydrochloride, mp 222-224 C.
E. A stirred mixtrue of 10.1 g of 3-(2-bromoethyl)-indole, 15.2 g of 4-(4-fluorobenzoyl)piperidine, and 15.0 g of anhydrous potassium carbonate in 150 ml of n-butanol is refluxed under nitrogen for three hours. The mixture is cooled, filtered, and ether is slowly added to the filtrate to precipitate a white solid, the starting piperidine, which is removed by filtration. The solvent is removed under reduced pressure, leaving a soft orange solid. The solid is dissolved in absolute ethanol, the solution is cooled, and HCl gas is bubbled into the solution. After standing about 5 minutes, - the salt precipitates as off-white needles. The needles are recrystallized from a methanol-ether mixture to give slightly off-white needles, mp 267-269 C (dec.) of 3-{2-L4-(4-fluoro-benzoyl)piperidyl] ethyl~ indole hydrochloride.Analysis:
` Calculated for C H FN O HCl: 68.29%C; 6.25%H; 7.24%N
~- Found: 68.08~C; 6.49%H; 7.32%N
1 1 _ ,: - :: : : .
1~78387 HOE 76/F 249 By following the manipulative procedure of step E, 3-~2-L4-(3-trifluoromethyl)piperidyl]ethyl~indole is prepared by substituting 4-(3-trifluoromethylbenzoyl)-piperidine for 4-(4-fluorobenzoyl)piperidine.
4-(3-trifluoromethylbenzoyl)piperidine is prepared in the following manner: A solution of 102.5 g of 3-bromo-benzotrifluoride in 25 ml of ether is added dropwise to a stirring mixture of 11.5 g of magnesium turnin~s in 300 ml of anhydrous ether to maintain a moderate reflux. After total addition the resulting dark mixture is stirred for 1 hour at ambient temperature. A solution of 60.0 g of 1-acetyl-4-cyanopiperidine in 100 ml of tetrahydrofuran is slowly added to this mixture and the mixture is stirred for 16 hours. An excess of an aqueous solution of ammonium chloride is added and the mixture is heated on a steam bath for 3 hours. The mixture is allowed to cool, extracted with ~enzene and the combined extracts are dried. The solvent is removed and the residue is dissolved in ethanol and basified with sodium hydroxide. The alkaline solution is refluxed for 3 hours, cooled and extracted with benzene. The combined benzene extracts are dried and the benzene is removed, leaving the oil, 4-(3-trifluoromethylbenzoyl)piperidine, which is converted to the hydrochloride, mp. 196-198 C.
A suspension of 2.8 g of 3-{2-L4-(4-fluorobenzoyl)-piperidyl ethyl~indole, free base of Example 1(e), in 180 ml of isopropanol is added dropwise to a stirred mixture of 102 g of sodium borohydride in 75 ml of `~ isopropanol at 5 C. After total addition, the mixture .. . -: :: : .. . ... : ;: :
. ~ .. , ~ . -: , . :
- . . - .. ~ : : :. . . . .
1~783~7 HOE 76/F 249 is permitted to reach ambient temperature, and is stirred for 4.5 hours. The solution is poured into water, the aqueous solution is extracted with methylene chloride, the organic layer is dried, and the solvent is removed under reduced pressure to give a yellow oil. The oil is stirred vigorously in the presence of hexane, and is crystallized to a white solid. The solid is recrystallized from acetonitrile and then from an ethanol-water mixture to give a white powder, mp 188-190C, of 3-~2-~4-(4-fluorophenylhydroxymethyl)-10 piperidyl3ethyl~ indole.
Analysis:
Calculated for C22H25FN2O: 74.96%C; 7.15%H; 7.gs%N; s.39%F.
Found: 74.85~C; 7.22%H; 8.02%N; 5.05%F.
A. By following the manipulative procedures described above in Example 1(c), and (d), 37.4 g of 1-acetylisonipecotoyl chloride, (Example 1(b)) and 40 g of aluminum chloride in 90 ml of chlorobenzene are reacted to produce 4-(4-chloro-benzoyl)piperidine hydrochloride. The salt is recrystallized thrice from an ethanol-ether mixture to give a white productJ
mp 233-235 C.
B. A solution of 13.0 g of 4-(4-chlorobenzoyl)-piperidine hydrochloride, 10.7 g of triethylamine and 9.8 g of 3-(2-bromoethyl)indole in 350 ml of dimethylformamide is stirred at ambient temperature for 42 hours. Water is added dropwise to the solution to precipitate a pale yellow solid. The solid is collected washed with water and dried. The solid is recrystallized from isopropanol - to give off-white flakes, mp 174-176 C, of 3-~2-C4-(4-. , . ......... . . . -, .
.
` 1~78387 HOE 76/F 249 chlorobenzoyl)piperidyl~ethyl~indole.
Analysis:
Calculated for C22H23ClN2O: 72.01%C; 6.31%H; 7.63~N; 9.66%Cl.
Found: 72.14%C; 6.26%H; 7.51%N; 9.76%Cl.
A. 32.0 g of 1-acetylisonipecotoyl chloride, Example 1(b) are added portionswise to a stirred mixture of 45.3 g of aluminum chloride, 28.3 g of bromobenzene and 120 ml of ethylene dichloride. The solution is stirred overnight, poured onto ice, the organic phase is collected, and the aaueous layer is extracted with chloroform. The organic solutions are combined, dried, and the solvent is removed under reduced pressure to give a yellow oil which crystallizes to a soft solid. The solid is triturated with ether, collected and dried to give 1-acetyl-4-(4-bromobenzoyl)piperidine.
B. A sample of 30.9 g of 1-acetyl-4-(4-bromobenzoyl)-piperidine is refluxed for 6 hours in 6N HCl, cooled, and the resulting insoluble salt is collected. The salt is recrystallized from an ethanol-ether mixture, then from isopropanol to give off-white crystals, mp 225-227C, 4-(4-bromobenzoyl)pipexidine hydrochloride.
C. A sample of 14.6 g of 4-(4-bromobenzoyl)piperidine hydrochloride is treated according to the manipulative proo~hue described above in Example 3(b) to produce a yellow solid. The solid is recrystallized from 95% ethanol(charcoal treatment) and then from a toluene-cyclohexane mixture to give an off-white solid, mp 178-180C, 3- ~-r4-(4-bromobenzoyl)-piperidyl3ethyl~indole.
Analysis:
~: . . . . . . . . , , . . ;. . , : : . .
. : . , : . : : :: ::: : .: .: .:: .
,: . . :. . . . : . . :: ,. :, ' ,: ,, ~.. , " :
.. . . .. . .
~ HOE 76/F 249 1(1 783~7 Calculated for C22H23BrN2O: 64.23%C; 5.64~H; 6.81%N; 19.43%Br.
Found: 64.08%C; 5.55%H; 6.61%N; 19.34~Br.
A. By following the manipulative procedures described above in Examples 1(c) and (d), 1-acetylisonipecotoyl chloride~
Example 1(b), toluene, and aluminum chloride are reacted to produce 4-(4-toluyl)piperidine hydrochloride. The salt is recrystallized thrice from a methanol-ether mixture (one charcoal treatment) to give colorless needles, mp 275-277C
(dec.).
B. By following the manipulative procedure described above in Example 3(b), 11.2 g of 4-(4-toluyl)piperidine, 6.1 g of triethylamine and 11.2 g of 3-(2-bromoethyl)indole are trea-ted to produce a white solid. The solid is recrystallized from 95% ethanol (charcoal treatment) to gi~e white flakes, mp 157.5-159C, of 3-~2 -L4- ( 4-toluoyl)piperidylJethyl~indole.
Analysis:
Calculated for C23H26N2O: 79.72%C; 7.56%H, 8.08%N.
Found: 79.69%C; 7.55%H; 8.02%N.
_ A. By following the manipulative procedure described above in Example 4(a), 32.0 g of 1-acetylisonipecotoyl chloride, (Example l(b)) are added to a stirring solution of 30.6 g of diphenylether and 45.3 g of aluminum chloride in 100 ml of ethylene dichloride to produce a yellow oil of 1-acetyl-4-(4-phenoxybenzoyl)piperidine.
B. A sample of 48.8 g of 1-acetyl-4-(4-phenoxybenzoyl)-piperidine is refluxed for 6 hours in 6N HCl. Upon cooling a white solid precipitateS from solution, is collected, , 1~78387 HOE 76/F 249 washed with water, then acetone, and dried. The filtrate is extracted with ether, the aqueous phase is basified with sodium hydroxide and extracted with benzene. The benzene is dried, and the solvent is removed under reduced pressure to S give a solid which is converted to a hydrochloride. The salt is recrystallized from an ethanol-ether mixture to give a white solid, mp 219-220C, 4-~4-phenoxybenzoyl)piperidine hydrochloride.
C. A solution of 10.3 g of 3-(2-bromoethyl)indole, 14.5 g 4-(4-phenoxybenzoyl)piperidine hydrochloride and 10 g of triethylamine in 350 ml of dimethylformamide is treated according to the manipulative procedure described above in Example 3(b) to produce a yellow solid. The solid is recrystallized thrice from a benzene-hexane mixture (one charcoal treatment) to give a pale yellow crystalline material, mp 180C, of 3-~2-[4-(4-phenoxybenzoyl)piperidyl~ ethyl~ indole.
Analysis:
C28H28N2O2: 79.22~C; 6.65%H; 6.60%N
Found: 79.07~C; 6.65%H; 6.52~N.
A. A sample of anisole is treated according to the manipulative procedu-res described above in Example 1(c) and (d) to produce 4-(4-methoxybenzoyl)piperidine hydro-chloride which, when recrystallized from isopropanol, had a mp of 251-256C.
B. A solution of 11.4 g of 4-(4-methoxybenzoyl)-piperidine, 10.1 g of 3-(2-bromoethyl)indole and 5.6 g of triethylamine in 500 ml of dimethylformamide is ~ treated according to the manipulative procedure described .~
,. ~ . . ; -, .: ,. : , , : :. ~
1~78387 HOE 76/F 249 above in Example 3(b) to produce a white solid. The solid is recrystallized twice from 95% ethanol (one charcoal treatment) to give silver-white flakes, mp 17S-177C of 3-~2-L4-(4-methoxy-benzoyl)piperidylJethyl~indole.
5 Analysis:
Calculated for C23H26N2O2 Found: 76.27%C; 7.32%H; 7.83%N.
-A. A sample of 18.0 of 1-acetyl-4-(4-methoxybenzoyl)-piperidine, the intermediate of Example 7(a), is refluxed with 300 ml of 48 % hydrogen bromide under nitrogen for 4 hours.
The solution is permitted to stand for 16 hours at 5C~ causing a white solid to precipitate. The solid is collected, washed well with acetone and dried. Recrystallization from methanol gives colorless needles, mp 273-275C, of 4-(4-hydroxybenzoyl)-piperidine hydrobromide.
B. A mixture of 9.7 g of 4-(4-hydroxybenzoyl)piperidine hydrobromide, 6.4 g of sodium bicarbonate and 7.0 g of 3-(2-bromoethyl)indole in 90 ml of dimethylsulfoxide is stirred overnight under nitrogen at 50C. After cooling to ambient tem-perature, water is added dropwise, precipitating a gummy brown solid. The supernatant solution is decanted from the solid, tritui^ated with water, collected, and dried. Recrystalli-zation from an ethanol-water mixture gives an off-white solid mp 212-214C (dec~ of 3-~2-~4-(4-hydroxybenzoyl)piperidyl~-ethyl~indole Analysis:
Calculated for C22H24N2O2:
; Found: 75.61%C; 6.85%H; 7.90%N.
~. , ,: : . . .: : , . :
. .
``-` 1(~783~7 A. A sample of benzene is treated according to the -manipulative procedures described above in Examples 1(c) and (d) to produce 4-(benzoyl)piperidine hydrochloride. The salt S is recrystallized from isopropanol to give a mp of 223-225C.
B. A solution of 10.4 g of 4-(benzoyl)piperidine, 6.1 g of triethylamine and 11.2 g of 3-(2-bromoethyl)indole in 350 ml of dimethylformamide is stirred at ambient temperature for 16 hours. Water is added dropwise, precipitating an off-white solid. The solid is collected, washed with water and low boiling petroleum ether, and dried. The solid is recrystallized from 95% ethanol to give white flakes, mp 145-147C of 3-L2-(4-benzovlpiperidyl)ethyl~indole.
Analysis:
Calculated for C22H24N2~: 79.48%C; 7.28%H; 8.43%N.
Found: 79.51%C; 7.33%H; 8.49%N.
E X A M P L E_ 10 A. By following the manipulative procedure described above in Example 4(a), 25 g of 1-acetylisonipecotoyl chloride are added to stirred suspension of 25 g of aluminum chloride and and 14 g of m-fluorotoluene in 220 ml of ethylene dichloride to produce the oil, 1-acetyl-4-(2-fluoro-4-methylbenzoyl)-piperidine.
B. A sample of 17.1 g of 1-acetyl-4-(2-fluoro-4-methyl-benzoyl)piperidine is refluxed in 200 ml of 6N HCl for 24hours and then stirred for an additional 6 hours at ambient temperature. The solution is extracted with ether, the aqueous layer is basified with 6N NaOH, extracted with benzene, dried and the solvent is removed under reduced pressure, leaving a .. . ........... . . .............. ,... , . - :.
:.. .. ~. ,. - ..: . ,. .. .
- : , , :. : . ,; : ., . , : i : . -:
: ` 10783~7 yellow oil. The oil is added ethereal hydrogen chloride and the resulting precipitate is collected, washed well with ether and dried. The solid is recrystallized from a methanol-ether ; mixture to give the final solid product, mp 220-221C of ; 5 4-(2-fluoro-4-methylbenzoyl)piperidine hydrochloride.
C. A solution of 15.5 g of 3-(2-bromoethyl)indole, 17.5 g of 4-(2-fluoro-4-methylbenzoyl)piperidine hydrochloride and 19 g of triethylamine in 500 ml of dimethylformamide is stirred at ambient temperature for 64 hours. Water is added dropwise, resulting in precipitate. The precipitate is collected by filtration, washed well with water and dried.
The solid is recrystallized from a methanol-ether mixture and from a benzene-hexane mixture to give off--~hite flakes, mp 117-118C, of 3-~2-~4-(2-fluoro-4-methylbenzoyl)piperidyl~-15 ethyl~indole.
Analysis:
Calculated for C23H25FNO2: 75.79~C; 6.92%H; 5.21%F; 7.6g~N.
Found: 75.96%C; 7.07%H; 5.15~F; 7.57%N.
E X A M P_L E _ 11 A. A sample o~ o-xylene is treated according to the manipulative procedures described above in Example 1(c) to give 1-acetyl-4-(3,4-dimethylbenzoyl)piperidine.
B. A sample of 21.3 g of 1-acetyl-4-(3,4-dimethylbenzoyl)-piperidine is refluxed in 100 ml 95~ ethanol and 100 ml 35%
potassium hydroxide for 6 hours and then allowed to stir at ambient temperature overnight. The aqueous layer is extracted with benzene, the organic extracts are combined and dried.
The solvent is removed under reduced pressure leaving a yellow oil. The oil is dissolved in ether and hydrogen chloride is ~ :: , 1C~78387 bubbled into the solution. The resulting solid precipitate is collected, washed well with ether and dried. The solid is recrystallized thrice from an isopropanol-ether mixture to give the salt, mp 258-259C, 4-(3,4-dimethylbenzoyl)piperidine hydrochloride.
C. A solution of 9.6 g of 3-(2-bromoethyl)indole, 11.5 g of 4-(3,4-dimethylbenzoyl)piperidine hydrochloride and 10.1 g of triethylamine in 300 ml of dimethylformamide is treated according to the manipulative procedure described in Example 3(b) to give an indole, which is purified on a silica gel column, eluted with a 5 ~ methanol-benzene mixture and recrystallized from an ethanol-water mixture to give the solid, mp 172-173C, 3-~2-C4-(3,4-dimethylbenzoyl)piperidyl~ -ethyl~indole.
15 Analysis:
Calculated for C24H28N2O: 79.96~C; 7.83~H; 7.77%N.
Found: 79.95%C; 7.90~H; 7.71%N.
A. 19.1 g of 1-acetylisonipecotoyl chloride, Example 1(b) are added portionswise to a stirring suspension of 13 g of ~-butylbenzene and 27 g of aluminum chloride in 175 ml of dichloroethane. The reaction mixture is refluxed for 1 hour, cooled, and poured onto ice. The organic layer is separated and the aqueous layer is extracted with chloroform. The organic layers are combined, dried, and the solvent is removed under reduced pressure leaving the oil, 1-acetyl-4-(4-t-butylbenzoyl)-piperidine.
B. A sample of 27.6 g of 1-acetyl-4-(4-t-butylbenzoyl)-piperidine is refluxed in 100 ml of ethanol and 100 ml of ~ . - . :,. :,,: , : ~ . :,. ..
1~783~7 HOE 76/F 249 35% aqueous potassium hydroxide for 6 hours, and then allowed to stir~ambient temperature for 62 hours. The solution is extracted with benzene, the benzene extracts are dried, and the benzene is removed under reduced pressure leaving an oil.
The oil is dissolved in ether and hydrogen chloride gas iS
bubbled into the solution. The resulting beige precipitate is collected and dried. The precipitate is recrystallized from 2-butanone to give the solid, mp 230-231C, 4-(4-t-butyl-benzoyl)piperidine hydrochloride.
C. A solution of 9.4 g of 3-(2-bromoethyl)indole, 11.7 g of 4-(4-t-butylbenzoyl)piperidine hydrochloride and 9 g of triethylamine in 350 ml of dimethylformamide is treated according to the manipulative procedure described in Example 3(b) to produce a yellow solid. The solid is recrystallized from a methanol-water mixture (charcoal treatment) then twice from a benzene-hexane mixture to give the off-white indole, mp 173-174C, 3-~2-L4-(4-t-butylbenzoyl)piperidyl~ethyl~indole.
Analysis:
Calculated for C26H32N2O: 80.37%C; 8.30~H; 7-21%N-Found: 80.15%C; 8.47%H; 7.07%N.E X A M P L E 13 A. 16.5 g of 1-acetylisonipecotoyl chloride, Example 1(b) are slowly added to a stirring mixture of 60 ml of m-dimethoxybenzene and 20.0 g of aluminum chloride. Stirring is continued for 1 hour at ambient temperature and then for an additional 1 hour at about 100 DC . The reaction mixture is allowed to cool to ambient temperature, poured into ice-water, and extracted with chloroform. The combined extracts are `- dried and the chloroform is removed leaving a yellow oil.
: . :: , ,, , , , . : :,, . , : .
.: : , ,.: ,... ,::. : ' .~ , The oil is triturated with hexane to effect a white solid which is collected and dried. Recrystallization from ethyl acetate yields colorless needles, mp 138-140C, 1-acetyl-4-(2-hydroxy-4-methoxybenzoyl)piperidine.
Analysis:
Calculated for C15H19NO4: 64.96%C; 6.90%H; 5.05%N.
Found: 65.05%C; 6.98%H; 4.92%N.
B. A sample of 1-acetyl-4-(2-hydroxy-4-methoxybenzoyl)-piperidine is treated according to the manipulative procedure described above in Example 1(d) to give 4-(2-hydroxy-4-methoxybenzoyl)piperidine.
C. A mixture of 4.0 g of 4-(2-hydroxy-4-methoxybenzoyl)-piperidine, 3.3 g of 3-(2-bromoethyl)indole and 1.4 g of sodium bicarbonate in 60 ml of dimethylsulfoxide is stirrea at ambient temperature for 42 hours and at 60C ~or an additional 6 hours. The reaction mixture is allowed to cool ; to ambient temperature and water is added dropwise to produce a gummy, brown precipitate. The precipitate is collected and triturated with ethanol to give a white solid which is recrystallized twice from ethanol (one charcoal treatment) to give silver-white flakes, mp 150-152C, 34 -~4-(2-hydroxy-4-methoxybenzoyl)piperidyl~ethyl~indole.
Analysis:
Calculated for C23H26 2 3 Found: 73.23%C; 6.92%H; 7.32%N.
A. 18.7 g of 1-acetylisonipecotoyl chloride, Example 1(b) are added slowly to a stirred mixture of 40.0 g of m-dimethoxybenzene and 19.2 g of aluminum chloride 10783~7 HOE 76/F 249 in 75 ml of carbon disulfide. The reaction mixture is stirred at ambient temperature for an hour, poured into ice-water and extracted with chLoroform, the combined extracts are dried ànd the chloroform is removed, leaving a yellow oil.
The oil is trit~rated with ether to give a white solid, which is recrystallized twice from ethyl acetate to give the pure solid, m~ 132-134C, 1-acetyl-4-(2,4-dimet~oxy-benzoyl)piperidine.
Analysis:
Ca cu ate o C16 21NO4: 65.95%C; 7.26%H; 4-80%N-Found: 65.86%C; 7.30%H; 4.63%N.
B. By following the manipulative procedure described above in Example 1(b), 7.4 g of 1-acetyl-4-(2,4-dimethoxy-benzoyl)piperidine in 250 ml of 6N HCl are treated to give a hydrogen chloride salt which is recrystallized once from an ethanol-ether mixture and twice from ethanol to give the compound, mp 198-200C, 4-(2,4-dimethoxy-benzoyl)-piperidine hydrochloride.
Analysis:
Calculated for C14H19NO3HCl: 58.84%C; 7.05%H; 4.90%N; 12.41%Cl.
Found: 58.97~C; 7.02%H; 5.11%N; 12.54%Cl.
C. To a stirring solution of 8.0 g of 4-(2,4-dimethoxy-benzoyl)piperidine hydrochloride and 6 ml of triethylamine in 250 ml of dimethylformamide is added a solution of 6.4 g of 3-(2-bromoethyl)indole in 50 ml of dimethylformamide. The reaction mixture is permitted to stir at ambient temperature for 72 hours and then 500 ml of water is added dropwise and extracted with chloroform. The combined extracts are dried - and most of the chloroform removed leaving a dark oil.
. . , -: ., :' ' . -.,,,' '' :.: : ,.
', .~:,, . . ' :, 107~387 HOE 76/F 249 The oil is subjected to column chromotography on a silica gel column and eluting with a 3% methanol in chloroform solution to give 3-~2- ~4-(2,4-dimethoxybenzoyl)piperidyl~ethyl~ indole.
The indole is recrystallized thrice from an ethanol-water 5 mixture to give the pure indole, mp 110-112C.
Analysis:
24 28 2 3 C; . ; ~ -Found: 73.4296C; 7.31%H; 7.18%N.
A. A few drops of ethyl bromide are added to a stirring suspension, under nitrogen, of 3.2 g of magnesium turnings in 10 ml of tetrahydrofuran. After a reaction begins, 17.7g of N-methyl-4-chloropiperidine in 50 ml of tetrahydrofuran are added dropwise while maintaining a moderate reflux. After total 15 addition, the reaction mixture is heated at reflux for 1 hour and 15.2 g of 3-tolylnitrile in 10 ml of tetrahydrofuran are slowly added. After this addition is complete the reaction mixture is heated at reflux for an additional 2 hours and then permitted to stir at ambient temperature for 16 hours.
20 The reaction mixture is poured into a solution of 35 g of ammonium chloride in 500 ml of ice-water and heated on a steam bath for 3 hours, cooled and extracted with benzene. The combined benzene extracts are dried and most of the benzene is removed, leaving an orange oil. The oil is dissolved in 25 ether and the oxalate salt is prepared by the addition of a solution of anhydrous oxalic acid in isopropanol. The white `~ oxalate salt is recrystallized twice from ethanol to give the product, mp 183-185C, 1-methyl-4-(3-toluyl)piperidine ;~ oxalate.
- - 107838~
Analysis:
Calculated for C14H19N-(CO2H)2: 62.53~C 6.89%H; 4.55%N.
Found: 62.32~C; 7.01%H; 4.52%N.
B. 18.8 g of phenylchloroformate are added dropwise to a solution of 21.3 g of 1-methyl-4-(3-toluyl)piperidine free base of the above, in 100 ml of methylene chloride and the reaction mixture is stirred at ambient temperature for 16 hours and the solvent removed leaving a dark brown semisolid. The semisolid is suspended in 500 ml of lN
hydrogen chloride solution and extracted with ether. Some of the desired material precipitates from the aqueous phase and is collected. The ether extract is dried and the ether removed under recuced pressure to give a brown solid, which is stirred in a 50~ methanol-2% aqueous potassium carbonate solution at ambient temperature for 16 hours. Filtration of the mixture provides more of the desired product. The combined product is recrystallized twice from an ethanol-water mixture to give the compound, 1-phenoxycarbonyl-4-(3-toluyl)piperidine, mp 127-130C.
Analysis:
r C12H21NO3: 74~28%C; 6.54%H; 4.33%N.
Found: 74.35%C; 6.62%H; 4.29%N.
C. A solution of 11.9 g of 1-phenoxycarbonyl-4-(3-toluyl)-piperidine and 75 ml of an aqueous 50 % potassium hydroxide solution in 300 ml of ethanol is heated at reflux for 24 hours and then stirred at ambient temperature for an additional 36 hours. 100 ml of water are added, the ethanol is partially removed, the resulting mixture is extracted with ether and the combined ether extracts are extracted with 1N HCl. The : . .,: , , aqueous solution is basified with an aqueous sodium hydroxide solution, extracted with ether, the combined ether extracts are dried, and the ether is removed, leaving a dark oil. The oil is dissolved in ether and ethereal hydrogen chloride is added to produce the salt which is collected by filtration, dried and recrystallized thrice from an ethanol-water mixture to give 4-(3-toluyl)piperidine hydrochloride, mp 196-197C.
Analysis:
Calculated for C13H17NOHCl: 65.13%C; 7.57%H; 5.83%N; 14.79%Cl.
Found: 64.90%C; 7.59%H; 5.73%N; 14.65~Cl.
D. 4.2 g of potassium carbonate are added to a stirred solution of 3.8 g of 4-(3-toluyl)piperidine hydrochloride in 400 ml of dimethylformamide. The mixture is stirred at ambient temperature for 1 hour and then a solution of 3.4 g of 3-(2-bromoethyl)indole in 100 ml of dimethylformamide is introduced. The resulting mixture is stirred at ambient tem-perature for 120 hours, filtered and 1.5 l of water added dropwise to effect a precipitate. The precipitate is collected and recrystallized thrice from ethanol (one charcoal treatment) to give the indole, mp 171-173C, 3-2- ~ -(3-toluyl)piperidyl~ -ethyl3indole.
Analysis:
Calculated for C23H26N2O: 79.93%C; 7.56%H; 8.09%N.
Found: 79.85%C; 7.71%H; 8.17%N.
A. By following the manipulative procedure outlined inExample 15~a), a sample of 2-fluorobenzonitrile is treated to produce a hydrochloride salt which is recrystallized ~` twice from an ethanol-ether mixture to qive off-white crystals, mp 167~169C, 4-(2-fluorobenzoyl)-~methylpiperidine hydrochloride.
Analysis:
Calculated for C13H16FNO HCl: 60.58%C; 6.65~H; 5.43%N; 7.37%F.
Found: 60.30%C; 6.78%H; 5.43%N; 7.59%F.
B. 47.0 g of phenylchloroformate are added to a stirring solution of 57.5 g of 4-(2-fluorobenzoyl)-1-methyl piperidine in 750 ml of toluene. The reaction mixture is refluxed for 5 hours, cooled to ambient temperature, filtered, and the solvent is removed leaving a light colored oil. The oil is triturated with hexane to give a crystalline material which is recrystallized twice from an ethanol-water mixture and once from ethanol to give the compound, mp 95-96C, 1-phenoxycarbonyl-4-(2-fluorobenzoyl)piperidine.
Analysis:
Calculated for C19H18FNO3: 69.71%C; 5.54%H; 4.28~N; 5.18%F.
Found: 69.45%C; 5.67~H; 4.13%N; 6.10%F.
C. A solution of 40.5 g of 1-phenoxycarbonyl-4-(2-fluor benzoyl)piperidine in 500 ml of ethanol and 500 ml of an aqueous 30% potassium hydroxide solution is stirred at a temperature slightly below reflux for 16 hours, allowed to cool to ambient temperature, diluted with water, and the ethanol is partially removed under reduced pressure. The resulting aqueous suspension is extracted with ether, the combined ether extracts are extracted with 1N hydrogen chloride and the aqueous acid solution is basified with an aqu~ous sodlum hydroxide solution. The basic solution is extracted with ether, the combined ether extracts are dried .~
and the ether is removed under reduced pressure leaving a .
:: ' ' ` ..................... :
.. . .
10783~7 dark oil. The oil is dissolved in a minimum amount of ethanol and ethereal-hydrogen chloride is added dropwise to effect a precipitate. The precipitate is collected by filtration, dried and recrystallized twice from an ethano~ether mixture to give a white solid, mp 185-187C, 4-(2-fluorobenzoyl)piperidine hydrochloride.
Analysis:
Calculated for C12H14FNO-HCl: 59.14%C; 6.20%H; 5.74%N; 7.80%F.
Found: 58.90%C; 6.36%H; 5.50%N; 7.56%F.
D. A solution of 9.1 g of 3-(2-bromoethyl)indole in Z 100 ml of dimethylformamide is added to a stirring solution of 11.2 g of 4-(2-fluorobenzoyl)piperidine hydrochloride and 13 g of potassium carbonate in 400 ml of dimethylformamide.
' The reaction mixture is stirred at ambient temperature for J 15 24 hours, and then 800 ml of water are added dropwise, yielding a dark precipitate. This mixture is again stirred at ambient temperature for 24 hours and filtered to give a yellow crystalline material which is recrystallized thrice from an ethanol-water mixture to give an off-white crystalline material, mp 106-108C, 3-{2-~4-(2-fluorobenzoyl~piperidyl~-ethyl~indole.
Analysis:
Calculated for C22H23FN2O: 75.40~C; 6.62%H; 7.gg~N.
Found: 75.41%C; 6.59%H; 8.03%N.
A solution of 11.8 g of 3-~2-bromoethyl)-2-methylindole~
20.3 g of 4~4-toluyl)piperidine (Example 5(a)) in 500 ml of dimethylformamide is treated according to the manipulative procedure described in Example 3(b) to give the off-white -, :
: ~ , .. . ,. , .,, :
, , ::: . .. ..
10783~7 solid, mp 192-194C, 2-methyl-3-{2-L4-(4-toluyl)piperidylJ-ethyl~ indole from ethanol.
Analysis:
Calculated for C24H28N2O: 79.96%C; 7.83~H; 7.77%N. ;
5 Found: 79.82%C; 7.80~H; 7.69~N.
A. By following the manipulative procedure described in Example 1S(a), (b) and (c), 2-tolylnitrile is treated to produce 4-(2-toluyl)piperidine hydrochloride.
B. To a stirring solution of 4.2 g of 4-(2-toluyl)-piperidine hydrochloride and 4.0 g of triethylamine in 150 ml of dimethylformamide is added 3.8 g of 3-(2-bromoethyl)-indole. The resulting solution is stirred at ambient tempera-ture for 70 hours and stirring is continued while 500 ml of water are added dropwise. An oil appears which is extracted from the solution with chloroform, the combined chloroform extracts are dried and the excess chloroform is removed, leaving an oil which crystallizes upon standing. The solid product is recrystallized from cyclohexane and then twice from an ethanol-water mixture to give flakes, mp 111-112C, 3-l2-L4-(2-toluyl)piperidyl3ethyl~indole.
Analysis:
Calculated for C23H26N2O: 79.73%C; 7.56%H; 8.09~N.
Found: 79.83%C; 7.69%H; 8.14%N.
A solution of 8.8 g of 3-t2-bromoethyl)-S-methoxy indole in 100 ml of dimethylformamide is added to a stirring mixture of 4-(4-toluyl)piperidine hydrochloride ` (Example 5(a~) and 10.1 g of potassium carbonate in 107~3~7 400 ml of dimethylformamide and the reaction mixture is stirred at ambient temperature for 80 hours and then at 50C for 10 additional hours. It is cooled to ambient temperature, filtered, and 2 liters of water are added dropwise to produce a precipitate. The precipitate is triturated with ether and eluted with a 5 % methanol in benzene solution through a silica gel co~umn. The precipitate is recrystallized from an ethanol-water mixture to give off-white crystals, mp 131-133C, 5-methoxy-3-~2-L4-'4-toluyl)piperidyl~ ethyl~indole.Analysis:
Calculated for C24H28N2 2 Found: 76.36~C; 7.45~H; 7.19%N.
A. By following the manipulative procedures outlined I in Examples 1(a), (b), (c) and (d), a sample of biphenyl ¦ is treated to produce 4-(4-phenylbenzoyl)piperidine.
B. A solution of 10.4 g of 4-(4-phenylbenzoyl)-piperidine, 8.8 g of 3-(2-bromoethyl)indole and 4.5 g of triethylamine in 300 ml of dimethylformamide is treated according to the manipulative procedure outlined in Example 3(b) to produce 3-~2-L4-(4-phenylbenzoyl)piperidyl~-ethyl~indole. The indole is recrystallized twice from ¦ an ethanol-water mixture (one charcoal treatment), thrice from a pyridine-water mixture, and twice from an ~ acetone-water mixture to give the product, mp 189-192C.
¦ Analysis:
Calculated for C28H28N2O: 82.32%C; 6.91%H; 6.85%N.
Found: 81.90%C; 7~09~H; 6.80%N.
' ' . ' ' ~ - ': , , . . ':
: . . ':
107838~
A. 8.7 g of oxalyl chloride are added dropwise to a stirring solution, cooled to about -10C, of 12.0 g of 5,6-dimethoxy-2-methylindole in 250 ml of ether. After S addition is complete, the mixture is stirred for 10 minutes, producing a bright orange precipitate of 5,6-dimethoxy-2-methyl-3-indole glyoxylyl chloride which is immediately used for the next step.
B. The above ether suspension of 5,6-dimethoxy-2-methyl-3-indoleglyoxylyl chloride is added portionswise I to a cooled stirring mixture of 4-benzoylpiperidine (Example 9(a)), 150 ml of water, 150 ml of chloroform and 25 g of potassium carbonate. The mixture is stirred for 16 hours at ambient temperature, the organic layer is - 15 separated and the solvent is removed, leaving a brown oil which is triturated with cyclohexane and then stirred for 16 hours with ether. A white solid results which is collected, dried and recrystallized thrice from methanol to give the compound, mp 188-190C, 4-benzoyl-1-(5,6- -dimethoxy-2-methylindol-3-ylglyoxyloyl)piperidine.
Analysis:
Calculated for C2s 26 2 5 69- 0%C; 6-Found: 68.98%C; 6.20%H; 6.38~N.
C. A suspension of 20.2 g of 4-benzoyl-1-(5,6-dimethoxy-2-methylindol-3-ylglyoxyloyl)piperidine in 200 ml of tetrahydrofuran is added dropwise to a stirring solution, under nitrogen at reflux, of 9.6 g of lithium aluminum hydride in 210 ml of tetrahydrofuran. Stirring and refluxing is continued for 3 hours, the mixture is cooled in an ice ,, , , , I ....... .... . . ... . . .
bath and the excess hydride is destroyed with water. The mixture is filtered and the filtrate is concentrated under reduced pressure, leaving an off-white foam which is triturated with cyclohexane to give an off-white powder.
The oxalate salt is prepared by dissolving the free base ~ ddin~
in isopropanol and slowly/a solution of oxalic acid in isopropanol. The insoluble oxalate salt is collected and recrystallized from ethanol to give white crystals, mp 152-154C, 5,6-dimethoxy-2-methyl-3- ~-(4-phenylhydroxymethyl-10 piperidyl)ethyl3indole oxalate.
Analysis:
Calculated for C25H32N23 (C2H)2 Found: 65.02%C; 6.87%H; 5.61%N.
A mixture of 6.2 g of 3-(3-bromopropyl)indole, 5.8 g of 4-(4-fluorobenzoyl)piperidine, free base of Example 1d, 3.8 g of potassium carbonate in 65 ml of dimethylforma-mide is stirred under nitrogen at 50C for 16 hours. The mix-ture is stirred while being allowed to cool to ambient tempe-rature and then 180 ml of water are added slowly causing a yellow oil to separate. The supernatant aqueous solution is decanted from the oil and the oil is taken up in ether, the ethereal solution is washed with water and dried and the ether removed in vacuo leaving a white solid. The solid is dissolved in absolute ethanol, and HCl gas bubbled into the solution to produce a salt. Addition of ether to the solu-tion causes the salt to precipitate. The salt is recrystal-lized from isopropanol to give the white solid, mp 211-213C
of 3-~3-~4-(4-fluorobenzoyl)piperidyl~ propyl~ indole hydro-.: . . . .. . .
. . . . . .. . . .
,, - . . -. ~ -,. , ,, .. :
.. ~ , . .. . ..
''' ' ' '" ~ ~ .
.
chloride.
Analysis:
Calculated for C23H25FNO2-HCl: 68.69~C; 6.54~H; 6.99%H; 8.84%Cl.
Found: 68.84%C; 6.60%H; 6.90%H; 8.65%Cl.
A sample of 3-3-~4-(4-fluorobenzoyl)piperidyl~-propyl~indole, free base of Example 22, is reduced and treated by the method described in Example 2 to give 3-~3-~4-(4-fluorophenylhydroxymethyl)piperidyl~propyl~indole.
A sample of 3-(3-bromopropyl)-6-methoxy-2-methylindole and 4-(3-fluorobenzoyl)piperidine are treated according to the method described in Example 1e to give 6-methoxy-2-methyl-3-~3-~4-(4-fluorobenzoyl)piperidyl3-propyl~ indole hydrochloride.
A sample of 6-methoxy-2-methyl-3-~3-~4-(4-fluoro-benzoyl)piperidyl3propyl~indole, free base of Example 24, is reduced and treated by the method described in Example 2 to give 6-methoxy-2-methyl-3-~3- L4- (4-fluorophenyl-hydroxymethyl)piperidyl~propyl~ indole.
The compounds of the present invention may be administered to a patient by a convenient route such as orally, intramuscu-larly, intraveneously, subcutaneously or intraperitoneally. The preferred route of administration is oral, for example, with an inert diluent or with an edible carrier or in gelatin capsules or tablets.
For the purpose of oral therapeutic administration, the active compounds of this invention may be incorporated with excipients and used in the form of tablets, troches, capsules elixirs, suspensions, syrups, wafers, chewing gum, and the like. These preparations should cont~in at least 0.5 % of active compound, but may be varied depending upon the particular form and may conveniently be between 7 % to about 70 % by weight of the unit. The amount of active compound in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form contains between 1 and 200 milligrams of active compound.
The tablets, pills, capsules, troches, and the like may also contain the following ingredients: a binder such as gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, potato starch and the like; a lubricant such as magnesium stearate;
~ and a sweetening agent such as sucrose or saccharin may be - . . ... . .. .. ., , . , ~ . -, , . - . . -., ~. : :: .i, .......... ,.. .. - ~ .... .. : . .
~,: , ' ' :
1~78387 HOE 76/F 249 added or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil. Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings.
Thus, tablets or pills may be coated with sugar, shellac, or both. A syrup may contain, in addition to the active compounds sucrose as a sweetening agent, and certain preservatives, dyes and colorings, and flavors. Materials used in preparing these various compositions must be pharmaceutically pure and non-toxic in the amounts utilized.
For the purpose of parenteral therapeutics administration, the active compounds of the invention may be incorporated into a solution of suspension. These preparations should con-tain at least 0.1 % of active compound, but may be varied to be between 0.5 and about 30 ~ of the weight thereof. The amount of active compound in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 0.5 to 100 milligrams of active compound.
The solutions or suspensions may also include the follo-wing components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol ~ methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as : : .~" :: .: , :.: ~ .-10783~7 HOE 76/F 249 acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
The parenteral preparation can be enclosed in ampules, disposable syringes or muItiple dose vials made of glass or plastic.
The invention is further illustrated by the following examples given for illustrative purposes.
E X A M P L E
A. A solution of 51.6 g of isonipecotic acid in 200 ml of acetic anhydride is refluxed for 2 hours and allowed to stir at ambient temperature for 16 hours. The solution is concentrated and the resulting residue is triturated in ether.
The solid is collected by filtration and recrystallized from an isopropyl alcohol-diisopropyl ether mixture giving 1-acetyl-isonipecotic acid as a white solid.
B. ~ sample of 65.4 g of 1-acetylisonipecotic acid is dissolved in 400 ml of thionyl chloride. The acid chloride precipitates from solution and one liter of petroleum ether is added. The mixture is filtered, the solid residue is washed several times with petroleum ether and dried, giving 1-acetyl-isonipecotoyl chloride as a white solid.
C. 70 g of 1-acetylisonipecotoyl chloride are slowly added to a stirring mixture of 93.0 g of aluminum chloride in 150 ml of fluorobenzene. After total addition, the mixture is *
poured onto ice and the two resulting layers separate. The aqueous layer is extracted twice with chloroform and the extracts are added to the fluorobenzene which separated previous-ly. The organic solution is dried and concentrated under " reduced pressure leaving a crystalline white solid. The solid *) refluxsd for one hour. The mixture is ., , ' ' . . ~ ' ' ,', . ` I ! ' ' '~, , ', .' ' '.'" "' ' ". ''' '' : ` ' ': '."' ' :. ' . ' ''" ~
~0783~ 7 HOE 76/F 249 is recrystalli~ed from a ligroin-diisopropyl ether mixture, producing 1-acetyl-4-(4-fluoro-benz~l)piperidine.
D. A solution of 70.6 g of 1-acetyl-4-(4-fluorobenzoyl)-piperidine in 200 ml of 6N HCl is refluxed for 2 hours. The cooled solution is extracted twice with ether, the aqueous solution basified with sodium hydroxide and then extracted with benzene. The benzene extracts are dried, filtered and the filtrate is concentrated under reduced pressure. The residual oil is dissolved in ether and HCl gas is bubbled into the solution with stirring. The salt is collected by filtration5 washed with ether and dried. The salt is recrystallized from isopropanol to give the solid product of 4-(4-fluorobenzoyl)-piperidine hydrochloride, mp 222-224 C.
E. A stirred mixtrue of 10.1 g of 3-(2-bromoethyl)-indole, 15.2 g of 4-(4-fluorobenzoyl)piperidine, and 15.0 g of anhydrous potassium carbonate in 150 ml of n-butanol is refluxed under nitrogen for three hours. The mixture is cooled, filtered, and ether is slowly added to the filtrate to precipitate a white solid, the starting piperidine, which is removed by filtration. The solvent is removed under reduced pressure, leaving a soft orange solid. The solid is dissolved in absolute ethanol, the solution is cooled, and HCl gas is bubbled into the solution. After standing about 5 minutes, - the salt precipitates as off-white needles. The needles are recrystallized from a methanol-ether mixture to give slightly off-white needles, mp 267-269 C (dec.) of 3-{2-L4-(4-fluoro-benzoyl)piperidyl] ethyl~ indole hydrochloride.Analysis:
` Calculated for C H FN O HCl: 68.29%C; 6.25%H; 7.24%N
~- Found: 68.08~C; 6.49%H; 7.32%N
1 1 _ ,: - :: : : .
1~78387 HOE 76/F 249 By following the manipulative procedure of step E, 3-~2-L4-(3-trifluoromethyl)piperidyl]ethyl~indole is prepared by substituting 4-(3-trifluoromethylbenzoyl)-piperidine for 4-(4-fluorobenzoyl)piperidine.
4-(3-trifluoromethylbenzoyl)piperidine is prepared in the following manner: A solution of 102.5 g of 3-bromo-benzotrifluoride in 25 ml of ether is added dropwise to a stirring mixture of 11.5 g of magnesium turnin~s in 300 ml of anhydrous ether to maintain a moderate reflux. After total addition the resulting dark mixture is stirred for 1 hour at ambient temperature. A solution of 60.0 g of 1-acetyl-4-cyanopiperidine in 100 ml of tetrahydrofuran is slowly added to this mixture and the mixture is stirred for 16 hours. An excess of an aqueous solution of ammonium chloride is added and the mixture is heated on a steam bath for 3 hours. The mixture is allowed to cool, extracted with ~enzene and the combined extracts are dried. The solvent is removed and the residue is dissolved in ethanol and basified with sodium hydroxide. The alkaline solution is refluxed for 3 hours, cooled and extracted with benzene. The combined benzene extracts are dried and the benzene is removed, leaving the oil, 4-(3-trifluoromethylbenzoyl)piperidine, which is converted to the hydrochloride, mp. 196-198 C.
A suspension of 2.8 g of 3-{2-L4-(4-fluorobenzoyl)-piperidyl ethyl~indole, free base of Example 1(e), in 180 ml of isopropanol is added dropwise to a stirred mixture of 102 g of sodium borohydride in 75 ml of `~ isopropanol at 5 C. After total addition, the mixture .. . -: :: : .. . ... : ;: :
. ~ .. , ~ . -: , . :
- . . - .. ~ : : :. . . . .
1~783~7 HOE 76/F 249 is permitted to reach ambient temperature, and is stirred for 4.5 hours. The solution is poured into water, the aqueous solution is extracted with methylene chloride, the organic layer is dried, and the solvent is removed under reduced pressure to give a yellow oil. The oil is stirred vigorously in the presence of hexane, and is crystallized to a white solid. The solid is recrystallized from acetonitrile and then from an ethanol-water mixture to give a white powder, mp 188-190C, of 3-~2-~4-(4-fluorophenylhydroxymethyl)-10 piperidyl3ethyl~ indole.
Analysis:
Calculated for C22H25FN2O: 74.96%C; 7.15%H; 7.gs%N; s.39%F.
Found: 74.85~C; 7.22%H; 8.02%N; 5.05%F.
A. By following the manipulative procedures described above in Example 1(c), and (d), 37.4 g of 1-acetylisonipecotoyl chloride, (Example 1(b)) and 40 g of aluminum chloride in 90 ml of chlorobenzene are reacted to produce 4-(4-chloro-benzoyl)piperidine hydrochloride. The salt is recrystallized thrice from an ethanol-ether mixture to give a white productJ
mp 233-235 C.
B. A solution of 13.0 g of 4-(4-chlorobenzoyl)-piperidine hydrochloride, 10.7 g of triethylamine and 9.8 g of 3-(2-bromoethyl)indole in 350 ml of dimethylformamide is stirred at ambient temperature for 42 hours. Water is added dropwise to the solution to precipitate a pale yellow solid. The solid is collected washed with water and dried. The solid is recrystallized from isopropanol - to give off-white flakes, mp 174-176 C, of 3-~2-C4-(4-. , . ......... . . . -, .
.
` 1~78387 HOE 76/F 249 chlorobenzoyl)piperidyl~ethyl~indole.
Analysis:
Calculated for C22H23ClN2O: 72.01%C; 6.31%H; 7.63~N; 9.66%Cl.
Found: 72.14%C; 6.26%H; 7.51%N; 9.76%Cl.
A. 32.0 g of 1-acetylisonipecotoyl chloride, Example 1(b) are added portionswise to a stirred mixture of 45.3 g of aluminum chloride, 28.3 g of bromobenzene and 120 ml of ethylene dichloride. The solution is stirred overnight, poured onto ice, the organic phase is collected, and the aaueous layer is extracted with chloroform. The organic solutions are combined, dried, and the solvent is removed under reduced pressure to give a yellow oil which crystallizes to a soft solid. The solid is triturated with ether, collected and dried to give 1-acetyl-4-(4-bromobenzoyl)piperidine.
B. A sample of 30.9 g of 1-acetyl-4-(4-bromobenzoyl)-piperidine is refluxed for 6 hours in 6N HCl, cooled, and the resulting insoluble salt is collected. The salt is recrystallized from an ethanol-ether mixture, then from isopropanol to give off-white crystals, mp 225-227C, 4-(4-bromobenzoyl)pipexidine hydrochloride.
C. A sample of 14.6 g of 4-(4-bromobenzoyl)piperidine hydrochloride is treated according to the manipulative proo~hue described above in Example 3(b) to produce a yellow solid. The solid is recrystallized from 95% ethanol(charcoal treatment) and then from a toluene-cyclohexane mixture to give an off-white solid, mp 178-180C, 3- ~-r4-(4-bromobenzoyl)-piperidyl3ethyl~indole.
Analysis:
~: . . . . . . . . , , . . ;. . , : : . .
. : . , : . : : :: ::: : .: .: .:: .
,: . . :. . . . : . . :: ,. :, ' ,: ,, ~.. , " :
.. . . .. . .
~ HOE 76/F 249 1(1 783~7 Calculated for C22H23BrN2O: 64.23%C; 5.64~H; 6.81%N; 19.43%Br.
Found: 64.08%C; 5.55%H; 6.61%N; 19.34~Br.
A. By following the manipulative procedures described above in Examples 1(c) and (d), 1-acetylisonipecotoyl chloride~
Example 1(b), toluene, and aluminum chloride are reacted to produce 4-(4-toluyl)piperidine hydrochloride. The salt is recrystallized thrice from a methanol-ether mixture (one charcoal treatment) to give colorless needles, mp 275-277C
(dec.).
B. By following the manipulative procedure described above in Example 3(b), 11.2 g of 4-(4-toluyl)piperidine, 6.1 g of triethylamine and 11.2 g of 3-(2-bromoethyl)indole are trea-ted to produce a white solid. The solid is recrystallized from 95% ethanol (charcoal treatment) to gi~e white flakes, mp 157.5-159C, of 3-~2 -L4- ( 4-toluoyl)piperidylJethyl~indole.
Analysis:
Calculated for C23H26N2O: 79.72%C; 7.56%H, 8.08%N.
Found: 79.69%C; 7.55%H; 8.02%N.
_ A. By following the manipulative procedure described above in Example 4(a), 32.0 g of 1-acetylisonipecotoyl chloride, (Example l(b)) are added to a stirring solution of 30.6 g of diphenylether and 45.3 g of aluminum chloride in 100 ml of ethylene dichloride to produce a yellow oil of 1-acetyl-4-(4-phenoxybenzoyl)piperidine.
B. A sample of 48.8 g of 1-acetyl-4-(4-phenoxybenzoyl)-piperidine is refluxed for 6 hours in 6N HCl. Upon cooling a white solid precipitateS from solution, is collected, , 1~78387 HOE 76/F 249 washed with water, then acetone, and dried. The filtrate is extracted with ether, the aqueous phase is basified with sodium hydroxide and extracted with benzene. The benzene is dried, and the solvent is removed under reduced pressure to S give a solid which is converted to a hydrochloride. The salt is recrystallized from an ethanol-ether mixture to give a white solid, mp 219-220C, 4-~4-phenoxybenzoyl)piperidine hydrochloride.
C. A solution of 10.3 g of 3-(2-bromoethyl)indole, 14.5 g 4-(4-phenoxybenzoyl)piperidine hydrochloride and 10 g of triethylamine in 350 ml of dimethylformamide is treated according to the manipulative procedure described above in Example 3(b) to produce a yellow solid. The solid is recrystallized thrice from a benzene-hexane mixture (one charcoal treatment) to give a pale yellow crystalline material, mp 180C, of 3-~2-[4-(4-phenoxybenzoyl)piperidyl~ ethyl~ indole.
Analysis:
C28H28N2O2: 79.22~C; 6.65%H; 6.60%N
Found: 79.07~C; 6.65%H; 6.52~N.
A. A sample of anisole is treated according to the manipulative procedu-res described above in Example 1(c) and (d) to produce 4-(4-methoxybenzoyl)piperidine hydro-chloride which, when recrystallized from isopropanol, had a mp of 251-256C.
B. A solution of 11.4 g of 4-(4-methoxybenzoyl)-piperidine, 10.1 g of 3-(2-bromoethyl)indole and 5.6 g of triethylamine in 500 ml of dimethylformamide is ~ treated according to the manipulative procedure described .~
,. ~ . . ; -, .: ,. : , , : :. ~
1~78387 HOE 76/F 249 above in Example 3(b) to produce a white solid. The solid is recrystallized twice from 95% ethanol (one charcoal treatment) to give silver-white flakes, mp 17S-177C of 3-~2-L4-(4-methoxy-benzoyl)piperidylJethyl~indole.
5 Analysis:
Calculated for C23H26N2O2 Found: 76.27%C; 7.32%H; 7.83%N.
-A. A sample of 18.0 of 1-acetyl-4-(4-methoxybenzoyl)-piperidine, the intermediate of Example 7(a), is refluxed with 300 ml of 48 % hydrogen bromide under nitrogen for 4 hours.
The solution is permitted to stand for 16 hours at 5C~ causing a white solid to precipitate. The solid is collected, washed well with acetone and dried. Recrystallization from methanol gives colorless needles, mp 273-275C, of 4-(4-hydroxybenzoyl)-piperidine hydrobromide.
B. A mixture of 9.7 g of 4-(4-hydroxybenzoyl)piperidine hydrobromide, 6.4 g of sodium bicarbonate and 7.0 g of 3-(2-bromoethyl)indole in 90 ml of dimethylsulfoxide is stirred overnight under nitrogen at 50C. After cooling to ambient tem-perature, water is added dropwise, precipitating a gummy brown solid. The supernatant solution is decanted from the solid, tritui^ated with water, collected, and dried. Recrystalli-zation from an ethanol-water mixture gives an off-white solid mp 212-214C (dec~ of 3-~2-~4-(4-hydroxybenzoyl)piperidyl~-ethyl~indole Analysis:
Calculated for C22H24N2O2:
; Found: 75.61%C; 6.85%H; 7.90%N.
~. , ,: : . . .: : , . :
. .
``-` 1(~783~7 A. A sample of benzene is treated according to the -manipulative procedures described above in Examples 1(c) and (d) to produce 4-(benzoyl)piperidine hydrochloride. The salt S is recrystallized from isopropanol to give a mp of 223-225C.
B. A solution of 10.4 g of 4-(benzoyl)piperidine, 6.1 g of triethylamine and 11.2 g of 3-(2-bromoethyl)indole in 350 ml of dimethylformamide is stirred at ambient temperature for 16 hours. Water is added dropwise, precipitating an off-white solid. The solid is collected, washed with water and low boiling petroleum ether, and dried. The solid is recrystallized from 95% ethanol to give white flakes, mp 145-147C of 3-L2-(4-benzovlpiperidyl)ethyl~indole.
Analysis:
Calculated for C22H24N2~: 79.48%C; 7.28%H; 8.43%N.
Found: 79.51%C; 7.33%H; 8.49%N.
E X A M P L E_ 10 A. By following the manipulative procedure described above in Example 4(a), 25 g of 1-acetylisonipecotoyl chloride are added to stirred suspension of 25 g of aluminum chloride and and 14 g of m-fluorotoluene in 220 ml of ethylene dichloride to produce the oil, 1-acetyl-4-(2-fluoro-4-methylbenzoyl)-piperidine.
B. A sample of 17.1 g of 1-acetyl-4-(2-fluoro-4-methyl-benzoyl)piperidine is refluxed in 200 ml of 6N HCl for 24hours and then stirred for an additional 6 hours at ambient temperature. The solution is extracted with ether, the aqueous layer is basified with 6N NaOH, extracted with benzene, dried and the solvent is removed under reduced pressure, leaving a .. . ........... . . .............. ,... , . - :.
:.. .. ~. ,. - ..: . ,. .. .
- : , , :. : . ,; : ., . , : i : . -:
: ` 10783~7 yellow oil. The oil is added ethereal hydrogen chloride and the resulting precipitate is collected, washed well with ether and dried. The solid is recrystallized from a methanol-ether ; mixture to give the final solid product, mp 220-221C of ; 5 4-(2-fluoro-4-methylbenzoyl)piperidine hydrochloride.
C. A solution of 15.5 g of 3-(2-bromoethyl)indole, 17.5 g of 4-(2-fluoro-4-methylbenzoyl)piperidine hydrochloride and 19 g of triethylamine in 500 ml of dimethylformamide is stirred at ambient temperature for 64 hours. Water is added dropwise, resulting in precipitate. The precipitate is collected by filtration, washed well with water and dried.
The solid is recrystallized from a methanol-ether mixture and from a benzene-hexane mixture to give off--~hite flakes, mp 117-118C, of 3-~2-~4-(2-fluoro-4-methylbenzoyl)piperidyl~-15 ethyl~indole.
Analysis:
Calculated for C23H25FNO2: 75.79~C; 6.92%H; 5.21%F; 7.6g~N.
Found: 75.96%C; 7.07%H; 5.15~F; 7.57%N.
E X A M P_L E _ 11 A. A sample o~ o-xylene is treated according to the manipulative procedures described above in Example 1(c) to give 1-acetyl-4-(3,4-dimethylbenzoyl)piperidine.
B. A sample of 21.3 g of 1-acetyl-4-(3,4-dimethylbenzoyl)-piperidine is refluxed in 100 ml 95~ ethanol and 100 ml 35%
potassium hydroxide for 6 hours and then allowed to stir at ambient temperature overnight. The aqueous layer is extracted with benzene, the organic extracts are combined and dried.
The solvent is removed under reduced pressure leaving a yellow oil. The oil is dissolved in ether and hydrogen chloride is ~ :: , 1C~78387 bubbled into the solution. The resulting solid precipitate is collected, washed well with ether and dried. The solid is recrystallized thrice from an isopropanol-ether mixture to give the salt, mp 258-259C, 4-(3,4-dimethylbenzoyl)piperidine hydrochloride.
C. A solution of 9.6 g of 3-(2-bromoethyl)indole, 11.5 g of 4-(3,4-dimethylbenzoyl)piperidine hydrochloride and 10.1 g of triethylamine in 300 ml of dimethylformamide is treated according to the manipulative procedure described in Example 3(b) to give an indole, which is purified on a silica gel column, eluted with a 5 ~ methanol-benzene mixture and recrystallized from an ethanol-water mixture to give the solid, mp 172-173C, 3-~2-C4-(3,4-dimethylbenzoyl)piperidyl~ -ethyl~indole.
15 Analysis:
Calculated for C24H28N2O: 79.96~C; 7.83~H; 7.77%N.
Found: 79.95%C; 7.90~H; 7.71%N.
A. 19.1 g of 1-acetylisonipecotoyl chloride, Example 1(b) are added portionswise to a stirring suspension of 13 g of ~-butylbenzene and 27 g of aluminum chloride in 175 ml of dichloroethane. The reaction mixture is refluxed for 1 hour, cooled, and poured onto ice. The organic layer is separated and the aqueous layer is extracted with chloroform. The organic layers are combined, dried, and the solvent is removed under reduced pressure leaving the oil, 1-acetyl-4-(4-t-butylbenzoyl)-piperidine.
B. A sample of 27.6 g of 1-acetyl-4-(4-t-butylbenzoyl)-piperidine is refluxed in 100 ml of ethanol and 100 ml of ~ . - . :,. :,,: , : ~ . :,. ..
1~783~7 HOE 76/F 249 35% aqueous potassium hydroxide for 6 hours, and then allowed to stir~ambient temperature for 62 hours. The solution is extracted with benzene, the benzene extracts are dried, and the benzene is removed under reduced pressure leaving an oil.
The oil is dissolved in ether and hydrogen chloride gas iS
bubbled into the solution. The resulting beige precipitate is collected and dried. The precipitate is recrystallized from 2-butanone to give the solid, mp 230-231C, 4-(4-t-butyl-benzoyl)piperidine hydrochloride.
C. A solution of 9.4 g of 3-(2-bromoethyl)indole, 11.7 g of 4-(4-t-butylbenzoyl)piperidine hydrochloride and 9 g of triethylamine in 350 ml of dimethylformamide is treated according to the manipulative procedure described in Example 3(b) to produce a yellow solid. The solid is recrystallized from a methanol-water mixture (charcoal treatment) then twice from a benzene-hexane mixture to give the off-white indole, mp 173-174C, 3-~2-L4-(4-t-butylbenzoyl)piperidyl~ethyl~indole.
Analysis:
Calculated for C26H32N2O: 80.37%C; 8.30~H; 7-21%N-Found: 80.15%C; 8.47%H; 7.07%N.E X A M P L E 13 A. 16.5 g of 1-acetylisonipecotoyl chloride, Example 1(b) are slowly added to a stirring mixture of 60 ml of m-dimethoxybenzene and 20.0 g of aluminum chloride. Stirring is continued for 1 hour at ambient temperature and then for an additional 1 hour at about 100 DC . The reaction mixture is allowed to cool to ambient temperature, poured into ice-water, and extracted with chloroform. The combined extracts are `- dried and the chloroform is removed leaving a yellow oil.
: . :: , ,, , , , . : :,, . , : .
.: : , ,.: ,... ,::. : ' .~ , The oil is triturated with hexane to effect a white solid which is collected and dried. Recrystallization from ethyl acetate yields colorless needles, mp 138-140C, 1-acetyl-4-(2-hydroxy-4-methoxybenzoyl)piperidine.
Analysis:
Calculated for C15H19NO4: 64.96%C; 6.90%H; 5.05%N.
Found: 65.05%C; 6.98%H; 4.92%N.
B. A sample of 1-acetyl-4-(2-hydroxy-4-methoxybenzoyl)-piperidine is treated according to the manipulative procedure described above in Example 1(d) to give 4-(2-hydroxy-4-methoxybenzoyl)piperidine.
C. A mixture of 4.0 g of 4-(2-hydroxy-4-methoxybenzoyl)-piperidine, 3.3 g of 3-(2-bromoethyl)indole and 1.4 g of sodium bicarbonate in 60 ml of dimethylsulfoxide is stirrea at ambient temperature for 42 hours and at 60C ~or an additional 6 hours. The reaction mixture is allowed to cool ; to ambient temperature and water is added dropwise to produce a gummy, brown precipitate. The precipitate is collected and triturated with ethanol to give a white solid which is recrystallized twice from ethanol (one charcoal treatment) to give silver-white flakes, mp 150-152C, 34 -~4-(2-hydroxy-4-methoxybenzoyl)piperidyl~ethyl~indole.
Analysis:
Calculated for C23H26 2 3 Found: 73.23%C; 6.92%H; 7.32%N.
A. 18.7 g of 1-acetylisonipecotoyl chloride, Example 1(b) are added slowly to a stirred mixture of 40.0 g of m-dimethoxybenzene and 19.2 g of aluminum chloride 10783~7 HOE 76/F 249 in 75 ml of carbon disulfide. The reaction mixture is stirred at ambient temperature for an hour, poured into ice-water and extracted with chLoroform, the combined extracts are dried ànd the chloroform is removed, leaving a yellow oil.
The oil is trit~rated with ether to give a white solid, which is recrystallized twice from ethyl acetate to give the pure solid, m~ 132-134C, 1-acetyl-4-(2,4-dimet~oxy-benzoyl)piperidine.
Analysis:
Ca cu ate o C16 21NO4: 65.95%C; 7.26%H; 4-80%N-Found: 65.86%C; 7.30%H; 4.63%N.
B. By following the manipulative procedure described above in Example 1(b), 7.4 g of 1-acetyl-4-(2,4-dimethoxy-benzoyl)piperidine in 250 ml of 6N HCl are treated to give a hydrogen chloride salt which is recrystallized once from an ethanol-ether mixture and twice from ethanol to give the compound, mp 198-200C, 4-(2,4-dimethoxy-benzoyl)-piperidine hydrochloride.
Analysis:
Calculated for C14H19NO3HCl: 58.84%C; 7.05%H; 4.90%N; 12.41%Cl.
Found: 58.97~C; 7.02%H; 5.11%N; 12.54%Cl.
C. To a stirring solution of 8.0 g of 4-(2,4-dimethoxy-benzoyl)piperidine hydrochloride and 6 ml of triethylamine in 250 ml of dimethylformamide is added a solution of 6.4 g of 3-(2-bromoethyl)indole in 50 ml of dimethylformamide. The reaction mixture is permitted to stir at ambient temperature for 72 hours and then 500 ml of water is added dropwise and extracted with chloroform. The combined extracts are dried - and most of the chloroform removed leaving a dark oil.
. . , -: ., :' ' . -.,,,' '' :.: : ,.
', .~:,, . . ' :, 107~387 HOE 76/F 249 The oil is subjected to column chromotography on a silica gel column and eluting with a 3% methanol in chloroform solution to give 3-~2- ~4-(2,4-dimethoxybenzoyl)piperidyl~ethyl~ indole.
The indole is recrystallized thrice from an ethanol-water 5 mixture to give the pure indole, mp 110-112C.
Analysis:
24 28 2 3 C; . ; ~ -Found: 73.4296C; 7.31%H; 7.18%N.
A. A few drops of ethyl bromide are added to a stirring suspension, under nitrogen, of 3.2 g of magnesium turnings in 10 ml of tetrahydrofuran. After a reaction begins, 17.7g of N-methyl-4-chloropiperidine in 50 ml of tetrahydrofuran are added dropwise while maintaining a moderate reflux. After total 15 addition, the reaction mixture is heated at reflux for 1 hour and 15.2 g of 3-tolylnitrile in 10 ml of tetrahydrofuran are slowly added. After this addition is complete the reaction mixture is heated at reflux for an additional 2 hours and then permitted to stir at ambient temperature for 16 hours.
20 The reaction mixture is poured into a solution of 35 g of ammonium chloride in 500 ml of ice-water and heated on a steam bath for 3 hours, cooled and extracted with benzene. The combined benzene extracts are dried and most of the benzene is removed, leaving an orange oil. The oil is dissolved in 25 ether and the oxalate salt is prepared by the addition of a solution of anhydrous oxalic acid in isopropanol. The white `~ oxalate salt is recrystallized twice from ethanol to give the product, mp 183-185C, 1-methyl-4-(3-toluyl)piperidine ;~ oxalate.
- - 107838~
Analysis:
Calculated for C14H19N-(CO2H)2: 62.53~C 6.89%H; 4.55%N.
Found: 62.32~C; 7.01%H; 4.52%N.
B. 18.8 g of phenylchloroformate are added dropwise to a solution of 21.3 g of 1-methyl-4-(3-toluyl)piperidine free base of the above, in 100 ml of methylene chloride and the reaction mixture is stirred at ambient temperature for 16 hours and the solvent removed leaving a dark brown semisolid. The semisolid is suspended in 500 ml of lN
hydrogen chloride solution and extracted with ether. Some of the desired material precipitates from the aqueous phase and is collected. The ether extract is dried and the ether removed under recuced pressure to give a brown solid, which is stirred in a 50~ methanol-2% aqueous potassium carbonate solution at ambient temperature for 16 hours. Filtration of the mixture provides more of the desired product. The combined product is recrystallized twice from an ethanol-water mixture to give the compound, 1-phenoxycarbonyl-4-(3-toluyl)piperidine, mp 127-130C.
Analysis:
r C12H21NO3: 74~28%C; 6.54%H; 4.33%N.
Found: 74.35%C; 6.62%H; 4.29%N.
C. A solution of 11.9 g of 1-phenoxycarbonyl-4-(3-toluyl)-piperidine and 75 ml of an aqueous 50 % potassium hydroxide solution in 300 ml of ethanol is heated at reflux for 24 hours and then stirred at ambient temperature for an additional 36 hours. 100 ml of water are added, the ethanol is partially removed, the resulting mixture is extracted with ether and the combined ether extracts are extracted with 1N HCl. The : . .,: , , aqueous solution is basified with an aqueous sodium hydroxide solution, extracted with ether, the combined ether extracts are dried, and the ether is removed, leaving a dark oil. The oil is dissolved in ether and ethereal hydrogen chloride is added to produce the salt which is collected by filtration, dried and recrystallized thrice from an ethanol-water mixture to give 4-(3-toluyl)piperidine hydrochloride, mp 196-197C.
Analysis:
Calculated for C13H17NOHCl: 65.13%C; 7.57%H; 5.83%N; 14.79%Cl.
Found: 64.90%C; 7.59%H; 5.73%N; 14.65~Cl.
D. 4.2 g of potassium carbonate are added to a stirred solution of 3.8 g of 4-(3-toluyl)piperidine hydrochloride in 400 ml of dimethylformamide. The mixture is stirred at ambient temperature for 1 hour and then a solution of 3.4 g of 3-(2-bromoethyl)indole in 100 ml of dimethylformamide is introduced. The resulting mixture is stirred at ambient tem-perature for 120 hours, filtered and 1.5 l of water added dropwise to effect a precipitate. The precipitate is collected and recrystallized thrice from ethanol (one charcoal treatment) to give the indole, mp 171-173C, 3-2- ~ -(3-toluyl)piperidyl~ -ethyl3indole.
Analysis:
Calculated for C23H26N2O: 79.93%C; 7.56%H; 8.09%N.
Found: 79.85%C; 7.71%H; 8.17%N.
A. By following the manipulative procedure outlined inExample 15~a), a sample of 2-fluorobenzonitrile is treated to produce a hydrochloride salt which is recrystallized ~` twice from an ethanol-ether mixture to qive off-white crystals, mp 167~169C, 4-(2-fluorobenzoyl)-~methylpiperidine hydrochloride.
Analysis:
Calculated for C13H16FNO HCl: 60.58%C; 6.65~H; 5.43%N; 7.37%F.
Found: 60.30%C; 6.78%H; 5.43%N; 7.59%F.
B. 47.0 g of phenylchloroformate are added to a stirring solution of 57.5 g of 4-(2-fluorobenzoyl)-1-methyl piperidine in 750 ml of toluene. The reaction mixture is refluxed for 5 hours, cooled to ambient temperature, filtered, and the solvent is removed leaving a light colored oil. The oil is triturated with hexane to give a crystalline material which is recrystallized twice from an ethanol-water mixture and once from ethanol to give the compound, mp 95-96C, 1-phenoxycarbonyl-4-(2-fluorobenzoyl)piperidine.
Analysis:
Calculated for C19H18FNO3: 69.71%C; 5.54%H; 4.28~N; 5.18%F.
Found: 69.45%C; 5.67~H; 4.13%N; 6.10%F.
C. A solution of 40.5 g of 1-phenoxycarbonyl-4-(2-fluor benzoyl)piperidine in 500 ml of ethanol and 500 ml of an aqueous 30% potassium hydroxide solution is stirred at a temperature slightly below reflux for 16 hours, allowed to cool to ambient temperature, diluted with water, and the ethanol is partially removed under reduced pressure. The resulting aqueous suspension is extracted with ether, the combined ether extracts are extracted with 1N hydrogen chloride and the aqueous acid solution is basified with an aqu~ous sodlum hydroxide solution. The basic solution is extracted with ether, the combined ether extracts are dried .~
and the ether is removed under reduced pressure leaving a .
:: ' ' ` ..................... :
.. . .
10783~7 dark oil. The oil is dissolved in a minimum amount of ethanol and ethereal-hydrogen chloride is added dropwise to effect a precipitate. The precipitate is collected by filtration, dried and recrystallized twice from an ethano~ether mixture to give a white solid, mp 185-187C, 4-(2-fluorobenzoyl)piperidine hydrochloride.
Analysis:
Calculated for C12H14FNO-HCl: 59.14%C; 6.20%H; 5.74%N; 7.80%F.
Found: 58.90%C; 6.36%H; 5.50%N; 7.56%F.
D. A solution of 9.1 g of 3-(2-bromoethyl)indole in Z 100 ml of dimethylformamide is added to a stirring solution of 11.2 g of 4-(2-fluorobenzoyl)piperidine hydrochloride and 13 g of potassium carbonate in 400 ml of dimethylformamide.
' The reaction mixture is stirred at ambient temperature for J 15 24 hours, and then 800 ml of water are added dropwise, yielding a dark precipitate. This mixture is again stirred at ambient temperature for 24 hours and filtered to give a yellow crystalline material which is recrystallized thrice from an ethanol-water mixture to give an off-white crystalline material, mp 106-108C, 3-{2-~4-(2-fluorobenzoyl~piperidyl~-ethyl~indole.
Analysis:
Calculated for C22H23FN2O: 75.40~C; 6.62%H; 7.gg~N.
Found: 75.41%C; 6.59%H; 8.03%N.
A solution of 11.8 g of 3-~2-bromoethyl)-2-methylindole~
20.3 g of 4~4-toluyl)piperidine (Example 5(a)) in 500 ml of dimethylformamide is treated according to the manipulative procedure described in Example 3(b) to give the off-white -, :
: ~ , .. . ,. , .,, :
, , ::: . .. ..
10783~7 solid, mp 192-194C, 2-methyl-3-{2-L4-(4-toluyl)piperidylJ-ethyl~ indole from ethanol.
Analysis:
Calculated for C24H28N2O: 79.96%C; 7.83~H; 7.77%N. ;
5 Found: 79.82%C; 7.80~H; 7.69~N.
A. By following the manipulative procedure described in Example 1S(a), (b) and (c), 2-tolylnitrile is treated to produce 4-(2-toluyl)piperidine hydrochloride.
B. To a stirring solution of 4.2 g of 4-(2-toluyl)-piperidine hydrochloride and 4.0 g of triethylamine in 150 ml of dimethylformamide is added 3.8 g of 3-(2-bromoethyl)-indole. The resulting solution is stirred at ambient tempera-ture for 70 hours and stirring is continued while 500 ml of water are added dropwise. An oil appears which is extracted from the solution with chloroform, the combined chloroform extracts are dried and the excess chloroform is removed, leaving an oil which crystallizes upon standing. The solid product is recrystallized from cyclohexane and then twice from an ethanol-water mixture to give flakes, mp 111-112C, 3-l2-L4-(2-toluyl)piperidyl3ethyl~indole.
Analysis:
Calculated for C23H26N2O: 79.73%C; 7.56%H; 8.09~N.
Found: 79.83%C; 7.69%H; 8.14%N.
A solution of 8.8 g of 3-t2-bromoethyl)-S-methoxy indole in 100 ml of dimethylformamide is added to a stirring mixture of 4-(4-toluyl)piperidine hydrochloride ` (Example 5(a~) and 10.1 g of potassium carbonate in 107~3~7 400 ml of dimethylformamide and the reaction mixture is stirred at ambient temperature for 80 hours and then at 50C for 10 additional hours. It is cooled to ambient temperature, filtered, and 2 liters of water are added dropwise to produce a precipitate. The precipitate is triturated with ether and eluted with a 5 % methanol in benzene solution through a silica gel co~umn. The precipitate is recrystallized from an ethanol-water mixture to give off-white crystals, mp 131-133C, 5-methoxy-3-~2-L4-'4-toluyl)piperidyl~ ethyl~indole.Analysis:
Calculated for C24H28N2 2 Found: 76.36~C; 7.45~H; 7.19%N.
A. By following the manipulative procedures outlined I in Examples 1(a), (b), (c) and (d), a sample of biphenyl ¦ is treated to produce 4-(4-phenylbenzoyl)piperidine.
B. A solution of 10.4 g of 4-(4-phenylbenzoyl)-piperidine, 8.8 g of 3-(2-bromoethyl)indole and 4.5 g of triethylamine in 300 ml of dimethylformamide is treated according to the manipulative procedure outlined in Example 3(b) to produce 3-~2-L4-(4-phenylbenzoyl)piperidyl~-ethyl~indole. The indole is recrystallized twice from ¦ an ethanol-water mixture (one charcoal treatment), thrice from a pyridine-water mixture, and twice from an ~ acetone-water mixture to give the product, mp 189-192C.
¦ Analysis:
Calculated for C28H28N2O: 82.32%C; 6.91%H; 6.85%N.
Found: 81.90%C; 7~09~H; 6.80%N.
' ' . ' ' ~ - ': , , . . ':
: . . ':
107838~
A. 8.7 g of oxalyl chloride are added dropwise to a stirring solution, cooled to about -10C, of 12.0 g of 5,6-dimethoxy-2-methylindole in 250 ml of ether. After S addition is complete, the mixture is stirred for 10 minutes, producing a bright orange precipitate of 5,6-dimethoxy-2-methyl-3-indole glyoxylyl chloride which is immediately used for the next step.
B. The above ether suspension of 5,6-dimethoxy-2-methyl-3-indoleglyoxylyl chloride is added portionswise I to a cooled stirring mixture of 4-benzoylpiperidine (Example 9(a)), 150 ml of water, 150 ml of chloroform and 25 g of potassium carbonate. The mixture is stirred for 16 hours at ambient temperature, the organic layer is - 15 separated and the solvent is removed, leaving a brown oil which is triturated with cyclohexane and then stirred for 16 hours with ether. A white solid results which is collected, dried and recrystallized thrice from methanol to give the compound, mp 188-190C, 4-benzoyl-1-(5,6- -dimethoxy-2-methylindol-3-ylglyoxyloyl)piperidine.
Analysis:
Calculated for C2s 26 2 5 69- 0%C; 6-Found: 68.98%C; 6.20%H; 6.38~N.
C. A suspension of 20.2 g of 4-benzoyl-1-(5,6-dimethoxy-2-methylindol-3-ylglyoxyloyl)piperidine in 200 ml of tetrahydrofuran is added dropwise to a stirring solution, under nitrogen at reflux, of 9.6 g of lithium aluminum hydride in 210 ml of tetrahydrofuran. Stirring and refluxing is continued for 3 hours, the mixture is cooled in an ice ,, , , , I ....... .... . . ... . . .
bath and the excess hydride is destroyed with water. The mixture is filtered and the filtrate is concentrated under reduced pressure, leaving an off-white foam which is triturated with cyclohexane to give an off-white powder.
The oxalate salt is prepared by dissolving the free base ~ ddin~
in isopropanol and slowly/a solution of oxalic acid in isopropanol. The insoluble oxalate salt is collected and recrystallized from ethanol to give white crystals, mp 152-154C, 5,6-dimethoxy-2-methyl-3- ~-(4-phenylhydroxymethyl-10 piperidyl)ethyl3indole oxalate.
Analysis:
Calculated for C25H32N23 (C2H)2 Found: 65.02%C; 6.87%H; 5.61%N.
A mixture of 6.2 g of 3-(3-bromopropyl)indole, 5.8 g of 4-(4-fluorobenzoyl)piperidine, free base of Example 1d, 3.8 g of potassium carbonate in 65 ml of dimethylforma-mide is stirred under nitrogen at 50C for 16 hours. The mix-ture is stirred while being allowed to cool to ambient tempe-rature and then 180 ml of water are added slowly causing a yellow oil to separate. The supernatant aqueous solution is decanted from the oil and the oil is taken up in ether, the ethereal solution is washed with water and dried and the ether removed in vacuo leaving a white solid. The solid is dissolved in absolute ethanol, and HCl gas bubbled into the solution to produce a salt. Addition of ether to the solu-tion causes the salt to precipitate. The salt is recrystal-lized from isopropanol to give the white solid, mp 211-213C
of 3-~3-~4-(4-fluorobenzoyl)piperidyl~ propyl~ indole hydro-.: . . . .. . .
. . . . . .. . . .
,, - . . -. ~ -,. , ,, .. :
.. ~ , . .. . ..
''' ' ' '" ~ ~ .
.
chloride.
Analysis:
Calculated for C23H25FNO2-HCl: 68.69~C; 6.54~H; 6.99%H; 8.84%Cl.
Found: 68.84%C; 6.60%H; 6.90%H; 8.65%Cl.
A sample of 3-3-~4-(4-fluorobenzoyl)piperidyl~-propyl~indole, free base of Example 22, is reduced and treated by the method described in Example 2 to give 3-~3-~4-(4-fluorophenylhydroxymethyl)piperidyl~propyl~indole.
A sample of 3-(3-bromopropyl)-6-methoxy-2-methylindole and 4-(3-fluorobenzoyl)piperidine are treated according to the method described in Example 1e to give 6-methoxy-2-methyl-3-~3-~4-(4-fluorobenzoyl)piperidyl3-propyl~ indole hydrochloride.
A sample of 6-methoxy-2-methyl-3-~3-~4-(4-fluoro-benzoyl)piperidyl3propyl~indole, free base of Example 24, is reduced and treated by the method described in Example 2 to give 6-methoxy-2-methyl-3-~3- L4- (4-fluorophenyl-hydroxymethyl)piperidyl~propyl~ indole.
Claims (28)
PROPERTY OR PRIVILEGE IS CLAIMED OR DEFINED AS FOLLOWS:
1. A process for the preparation for the compound of the formula I
I
wherein X represents C or CHOH; R represents hydrogen or methyl;
R1 and R2 are the same or different and represent hydrogen, halogen, straight or branched chain alkyl or up to 5 carbon atoms, alkoxy of up to 5 carbon atoms, trifluoromethyl, hydroxy, phenoxy or phenyl; R3 and R4 represent hydrogen or methoxy; n is the integer 1 or 2; and the acid addition salts thereof with pharmaceutically acceptable acids, in which, (a) a 3-(.omega.-bromoalkyl)indole of the formula II
II
wherein R, R3, R4 and n are as defined above, is reacted with a 4-benzoylpiperidine of the formula III
III
wherein R1 and R2 are as defined above, to form a compound of the formula I wherein X is C, and that compound may be reduced to form a compound of the formula I, wherein X is CHOH; or (b) to prepare a compound of the formula I wherein X represents CHOH and R, R1, R2, R3 and R4 are as defined above and n represents 1, an indole of the formula IV
IV
wherein R, R3 and R4 are as defined above, is reacted with an oxalyl halogenide to form a corresponding 3-indolgyloxylyl chloride, this product is reacted with a 4-benzoylpiperidine of the formula V
V
wherein R1 and R2 are as defined above to form a corresponding 4-benzoyl-1-(indol-3-ylglyoxyloyl)piperidine and said compound is reduced; and to prepare a salt, the product is reacted with a pharmaceutically acceptable acid.
I
wherein X represents C or CHOH; R represents hydrogen or methyl;
R1 and R2 are the same or different and represent hydrogen, halogen, straight or branched chain alkyl or up to 5 carbon atoms, alkoxy of up to 5 carbon atoms, trifluoromethyl, hydroxy, phenoxy or phenyl; R3 and R4 represent hydrogen or methoxy; n is the integer 1 or 2; and the acid addition salts thereof with pharmaceutically acceptable acids, in which, (a) a 3-(.omega.-bromoalkyl)indole of the formula II
II
wherein R, R3, R4 and n are as defined above, is reacted with a 4-benzoylpiperidine of the formula III
III
wherein R1 and R2 are as defined above, to form a compound of the formula I wherein X is C, and that compound may be reduced to form a compound of the formula I, wherein X is CHOH; or (b) to prepare a compound of the formula I wherein X represents CHOH and R, R1, R2, R3 and R4 are as defined above and n represents 1, an indole of the formula IV
IV
wherein R, R3 and R4 are as defined above, is reacted with an oxalyl halogenide to form a corresponding 3-indolgyloxylyl chloride, this product is reacted with a 4-benzoylpiperidine of the formula V
V
wherein R1 and R2 are as defined above to form a corresponding 4-benzoyl-1-(indol-3-ylglyoxyloyl)piperidine and said compound is reduced; and to prepare a salt, the product is reacted with a pharmaceutically acceptable acid.
2. A compound of the formula I as defined in claim 1, and the acid addition salts thereof, whenever obtained according to a process as claimed in claim 1 or by an obvious chemical equivalent thereof.
3. A process as claimed in claim 1 in which the preparation is carried out according to reaction (a) in an organic solvent at a temperature of from 20°C to the boiling point of the solvent and for a period of from 30 minutes to 120 hours.
4. A compound of the formula I as defined in claim 1, and the acid addition salts thereof, wherein X, R, R1, R2, R3, R4 and n are as defined for the formula I in claim 1, whenever obtained according to a process as claimed in claim 3 or by an obvious chemical equivalent thereof.
5. A process as claimed in claim 1 in which the preparation is carried out according to reaction (b) in which the compound of the formula IV is reacted with the oxalyl halogenide in a solvent at a temperature of from -15 to 15°C, the product is reacted with the compound of the formula V at a temperature of from 15 to 40°C and the resultant product is then reduced using lithium aluminum hydride.
6. A compound of the formula I as defined in claim 1, and the acid addition salts thereof, wherein X represents CHOH, R, R1, R2, R3 and R4 are as defined for the formula I in claim 1 and n represents 1, whenever obtained according to a process as claimed in claim 5 or by an obvious chemical equivalent thereof.
7. A process as claimed in claim 1 for the preparation of 3- 2-[4-(3,4-dimethylbenzoyl)piperidyl]ethyl indole in which 3-(2-bromoethyl)indole is reacted with 4-(3,4-dimethylbenzoyl)-piperidine hydrochloride in dimethylformamide in the presence of triethylamine and the product is subsequently isolated.
8. 3-{2-[4-(3,4-Dimethylbenzoyl)piperidyl]ethyl}indole, whenever obtained according to a process as claimed in claim 7 or by an obvious chemical equivalent thereof.
9. A process as claimed in claim 1 for the preparation of 3-{2-14-(2-fluoro-4-methylbenzoyl)piperidyl]ethyl}indole in which 3-(2-bromoethyl)indole is reacted with 4-(2-fluoro-4-methylbenzoyl)piperidine hydrochloride in dimethylformamide in the presence of triethylamine and the product is subsequently isolated.
10. 3-{2-[4-(2-Fluoro-4-methylbenzoyl)piperidyl]ethyl}
indole, whenever obtained according to a process as claimed in claim 9 or by an obvious chemical equivalent thereof.
indole, whenever obtained according to a process as claimed in claim 9 or by an obvious chemical equivalent thereof.
11. A process as claimed in claim 1 for the preparation of 3-{2-[4-(2-fluorobenzoyl)piperidyl]ethyl}indole in which 3-(2-bromoethyl)indole is reacted with 4-(2-fluoro-benzoyl)piperidine hydrochloride in dimethylformamide in the presence of potassium carbonate and the product is subsequently isolated.
12. 3-{2-[4-(2-Fluorobenzoyl)piperidyl]ethyl}indole whenever obtained according to a process as claimed in claim 11 or by an obvious chemical equivalent thereof.
13. A process as claimed in claim 1 for the preparation of 3-{2-[4-(2-hydroxy-4-methoxybenzoyl)piperidyl]ethyl}indole in which 4-(2-hydroxy-4-methoxybenzoyl)piperidine is reacted with 3-(2-bromethyl)indole in dimethylsulfoxide in the presence of sodium bicarbonate and the product is subsequently isolated.
14. 3-{2-[4-(2-Hydroxy-4-methoxybenzoyl)piperidyl]-ethyl}indole, whenever obtained according to a process as claimed in claim 13 or by an obvious chemical equivalent thereof.
15. A process as claimed in claim 1 for the preparation of 3-{3-[4-(4-fluorobenzoyl)piperidyl]propyl}indole hydrochloride in which 3-(3-bromopropyl)indole is reacted with 4-(4-fluoro-benzoyl)piperidine in the presence of potassium carbonate, the product is isolated, dissolved in ethanol, reacted with hydrogen chloride gas and the resultant product is subsequently isolated.
16. 3-{3-[4-(4-Fluorobenzoyl)piperidyl]propyl}indole hydro-chloride, whenever obtained according to a process as claimed in claim 15 or by an obvious chemical equivalent thereof.
17. A process as claimed in claim 1 for the preparation of 3-{2-[4-(4-fluorobenzoyl)piperidyl]ethyl}indole hydrochloride in which 3-(2-bromoethyl)indole is reacted with 4-(4-fluoro-benzoyl)piperidine in n-butanol in the presence of anhydrous potassium carbonate, the product is isolated, dissolved in ethanol, reacted with hydrogen chloride gas and the resultant product is subsequently isolated.
18. 3-{2-[4-(4-Fluorobenzoyl)piperidyl]ethyl} indole hydrochloride, whenever obtained according to a process as claimed in claim 17 or by an obvious chemical equivalent thereof.
19. A process as claimed in claim 1 for the preparation of 3-[2-(4-benzoylpiperidyl)ethyl]indole in which 4-(benzoyl) piperidine is reacted with 3-(2-bromoethyl)indole in dimethylformamide in the presence of triethylamine and the product is subsequently isolated.
20. 3-[2-(4-Benzoylpiperidyl)ethyl]indole whenever obtained according to a process as claimed in claim 19 or by an obvious chemical equivalent thereof.
21. A process as claimed in claim 1 for the preparation of 3-{2-[4-(4-toluoyl)piperidyl]ethyl}indole in which 4-(4-toluyl)piperidine is reacted with 3-(2-bromoethyl)indole in dimethylformamide in the presence of triethylamine and the product is subsequently isolated.
22. 3-{2-14-(4-toluoyl)piperidyl]ethyl}indole, whenever obtained according to a process as claimed in claim21 or by an obvious chemical equivalent thereof.
23. A process as claimed in claim 1 for the preparation of 3-{2-[4-(4-chlorobenzoyl)piperidyl]ethyl}indole in which 4-(4-chlorobenzoyl)-piperidine hydrochloride is reacted with 3-(2-bromoethyl)indole in dimethylformamide in the presence of triethylamine and the product is subsequently isolated.
24. 3-{2-[4-(4-chlorobenzoyl)piperidyl]ethyl} indole whenever obtained according to a process as claimed in claim 23, or by an obvious chemical equivalent thereof.
25. A process as claimed in claim 1 for the preparation of 3-{2-[4-(4-fluorophenylhydroxymethyl)piperidyl]ethyl}indole in which 3-(2-bromoethyl)indole is reacted with 4-(4-fluoro-benzoyl)piperidine in n-butanol in the presence of anhydrous potassium carbonate, the resultant product is isolated, dissolved in isopropanol, treated with sodium borohydride and the product is subsequently isolated.
26. 3-{2-[4-(4-Fluorophenylhydroxymethyl)piperidyl]
ethyl}indole, whenever obtained according to a process as claimed in claim 25, or by an obvious chemical equivalent thereof.
ethyl}indole, whenever obtained according to a process as claimed in claim 25, or by an obvious chemical equivalent thereof.
27. A process as claimed in claim 1 for the preparation of 3-{2-[4-(4-bromobenzoyl)piperidyl]ethyl}indole in which 4-(4-bromobenzoyl)piperidine hydrochloride is reacted with 3-(2-bromoethyl)indole in dimethylformamide in the presence of triethylamine and the product is subsequently isolated.
28. 3-{2-[4-(4-bromobenzoyl)piperidyl]ethyl}indole, whenever obtained according to a process as claimed in claim 27 or by an obvious chemical equivalent thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA273,782A CA1078387A (en) | 1977-03-11 | 1977-03-11 | Benzoylpiperidylalkylindoles and related compounds |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA273,782A CA1078387A (en) | 1977-03-11 | 1977-03-11 | Benzoylpiperidylalkylindoles and related compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1078387A true CA1078387A (en) | 1980-05-27 |
Family
ID=4108135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA273,782A Expired CA1078387A (en) | 1977-03-11 | 1977-03-11 | Benzoylpiperidylalkylindoles and related compounds |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1078387A (en) |
-
1977
- 1977-03-11 CA CA273,782A patent/CA1078387A/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4110459A (en) | Benzoylpiperidylalkylindoles in alleviating pain | |
| US3959475A (en) | Substituted 1,3-dihydrospiro(isobenzofuran)s | |
| CA1280421C (en) | 1,4-disubstituted piperidinyl derivatives | |
| US5071859A (en) | N-substituted azaheterocyclic carboxylic acids and pharmaceutical uses | |
| EP0080104B1 (en) | 3-(4-piperidyl)-1,2-benzisoxazoles, process for the preparation thereof, and a pharmaceutical composition comprising the same | |
| US4783471A (en) | N-aralkyl piperidine methanol derivatives and the uses thereof | |
| US4031221A (en) | Method of treating pain and hypertension | |
| NO831466L (en) | NEW DERIVATIVES OF AREN- AND HETEROAR-CARBOXAMIDES | |
| NO803453L (en) | PROCEDURE FOR THE PREPARATION OF PIPERIDYLBENZIMIDAZOLONE DERIVATIVES | |
| FR2471981A1 (en) | NOVEL DERIVATIVES OF (PIPERIDYL-4) -2 (QUINOLYL-4) -1 ETHANONE, INTERMEDIATE PRODUCTS AND PROCESSES FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | |
| CA1086742A (en) | Preparation of 1-substituted-4-aroyl-4-hydroxy and -4- acyloxypiperidines | |
| CA2072520A1 (en) | 2-(1-piperidyl) ethanol derivatives, their preparation and their therapeutic application | |
| US3532702A (en) | 2-(o-aminophenoxy or phenylthio) phenyl-1-substituted (piperidyl or pyrrolidinyl) ketones | |
| US4975431A (en) | Certain anti-inflammatory cyclohepta[b]pyridines and analogs thereof | |
| US5760035A (en) | Therapeutic agents | |
| US4046900A (en) | Benzoylpiperidylalkylindoles | |
| CA1078387A (en) | Benzoylpiperidylalkylindoles and related compounds | |
| US4521537A (en) | Spiro[2H-1,4-benzodioxepin-3(5H)4'-piperidine and -3'-pyrrolidine] compounds and their use as antihypertensive agents | |
| US5322848A (en) | N-acyl-substituted azacyclic compounds, processes for their preparation, and their use as pharmaceuticals | |
| US4593037A (en) | 1,3-disubstituted piperidine compounds as neuroleptic agents | |
| US4623728A (en) | Intermediates for 1,3-disubstituted piperidine compounds as neuroleptic agents | |
| US3982001A (en) | 4-(3.4-Methylene dioxy phenyl)-piperidines | |
| US4859700A (en) | 2-(2,3-dihydro-2-oxo-3-benzofuranyl)acetic acid compounds having antihypoxic and nootropic effects | |
| US4101660A (en) | 2-Aminomethyl-5-phenyloxazoles and the pharmaceutically acceptable acid addition salts thereof | |
| JP2006508110A (en) | Novel 2,3-dihydro-4 (1H) -pyridinone derivatives, processes for their preparation and pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |